

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

02 January 2020 (02.01.2020)



(10) International Publication Number

WO 2020/006476 A1

(51) International Patent Classification:

C07D 307/77 (2006.01) C07F 7/10 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2019/039925

(22) International Filing Date:

28 June 2019 (28.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/692,227 29 June 2018 (29.06.2018) US

(71) Applicant: **GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.** [US/US]; 30 Courtland Street, Alumni Hall, Suite 326, Atlanta, Georgia 30303 (US).

(72) Inventor: **XU, Hao**; c/o Georgia State University Research Foundation, Inc., 30 Courtland Street, Alumni Hall, Suite 326, Atlanta, Georgia 30303 (US).

(74) Agent: **BELLOWS, Brent R.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: ENVIRONMENTALLY-FRIENDLY HYDROAZIDATION OF OLEFINS

(57) Abstract: The present invention provides processes for the synthesis of organic azides, intermediates for the production thereof, and compositions related thereto.



WO 2020/006476 A1

ENVIRONMENTALLY-FRIENDLY HYDROAZIDATION OF OLEFINS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of provisional U.S. Application No. 62/692,227 filed
5 June 29, 2018. The entirety of this application is incorporated by reference.

FIELD OF THE INVENTION

The present invention provides processes for the synthesis of organic azides, intermediates
for the production thereof, and compositions related thereto.
10

BACKGROUND OF THE INVENTION

Nitrogen atoms are common components of small-molecule pharmaceuticals and other
biomaterials. While processes for the introduction of nitrogen into molecules by functional group
transformations have been employed for decades, those that proceed by the direct functionalization
15 of inexpensive hydrocarbon starting materials are less common. Processes for hydrocarbon
nitrogen functionalization that avoid the use of toxic transition metals are even rarer. Heavy metal
contamination must be removed or avoided altogether in the synthesis of compounds that are
intended for use in biological systems. Further, many well-established processes for the
introduction of nitrogen in molecules are not environmentally friendly due to their use of
20 stoichiometric levels of reagents.

There is a clear need for more efficient, atom-economical, and environmentally-friendly
processes for the synthesis of nitrogen-containing molecules.

There is also a need for processes for the synthesis of nitrogen-containing molecules that
do not use heavy metals.
25

SUMMARY OF THE INVENTION

The present invention provides processes for the synthesis of organic azides or azide-
functionalized oligomers or polymers by the reaction of an olefin, a silyl azide, and a hydrogen
bond donor in the presence of an organic promoter, which is accomplished in an environmentally-
30 friendly and atom-economical manner that does not require the use of metal catalysis. The organic
azides provided hereby can be used to create a wide range of nitrogen-containing organic

molecules, including those of pharmaceutical and biological interest. The process can also be used to make nitrogen-containing industrial organic compounds.

In particular, the present processes allow for the synthesis of organic azides from cheap olefin feedstocks instead of more expensive pre-functionalized materials that often require multiple transformations and purifications to obtain the desired product. The present process is significantly more atom economical than previous azide synthetic processes that produced stoichiometric levels of byproducts. The processes described herein also allow for the direct synthesis of hydroazidation products without the use of heavy metals, instead using an organic promoter to mediate the transformation. The prior art metal-mediated or catalyzed transformations often require significant additional purification steps to remove metal contaminants from the final products. This is particularly necessary in pharmaceutical and biological applications where metal contamination can often have detrimental toxicity. Additionally, the lack of heavy metals avoids the risk of accidental formation of explosive metal azide byproducts. The present processes are also safer for operators because they avoid the use of stoichiometric quantities of the highly volatile, toxic, and explosive reagent hydrazoic acid, and instead use silyl azide reagents that are commercially available and easier to handle. In addition, the presently disclosed processes are redox neutral, avoiding the use of stoichiometric oxidants, stoichiometric reductants, or the use of energy-intensive electrochemical processes to facilitate the transformation, an improvement over many azidation processes that have been previously reported. The currently disclosed process goes through a free radical-based mechanism to produce the organic azides from simple olefins.

According to the prior art, alkyl azides are typically prepared by nucleophilic displacement of a leaving group, such a halogen or sulfonate, with sodium azide. Hydroazidation reactions involving addition across a double bond have been more rarely reported. Markovnikov addition of hydrazoic acid (HN_3) has been reported across a limited subset of strained and reactive olefins, most likely preceding through the intermediacy of stabilized tertiary and benzylic carbocations (see Hassner, A. et al. *Journal of Organic Chemistry* **1984**, 49, 4237; and Breton, G. W. et al. *Journal of Organic Chemistry* **1992**, 57, 6646). Erick Carreira and coworkers have reported a cobalt-catalyzed Markovnikov hydroazidation reaction using electrophilic sulfonyl azides (see Waser, J. et al. *Journal of the American Chemical Society* **2005**, 127, 8294; and Waser, J. et al. *Journal of the American Chemical Society* **2006**, 128, 11693). Dale Boger and coworkers have

similarly reported an iron-mediated Markovnikov hydroazidation reaction using sodium azide (see Leggans, E. K. et al. *Organic Letters* **2012**, *14*, 1428).

Until now, anti-Markovnikov hydroazidations of unfunctionalized olefins have been comparatively under-developed. Multi-step stoichiometric processes are more common. A four-
5 step hydroboration-oxidation-mesylation-azidation sequence results in a formal anti-Markovnikov hydroazidation of an olefin (e.g., see Yang, Y. et al. *Organic Letters* **2014**, *16*, 6216). Phillipe Renaud and coworkers have reported a two-step hydroazidation protocol wherein a stoichiometric amount of an intermediate organoborane is formed via anti-Markovnikov olefin hydroboration, and the organoborane is subsequently reacted with a sulfonyl azide in the presence of a radical
10 initiator to furnish an organic azide in a second step (see Kapat, A. et al. *Journal of the American Chemical Society* **2011**, *133*, 13890; and Meyer D. and Renaud, P. *Angewandte Chemie International Edition* **2017**, *56*, 10858). Shunsuke Chiba, Fabien Gagosz, and coworkers have described an anti-Markovnikov hydroazidation reaction that requires the presence of benzylic groups within the substrate so that they may be used as hydrogen donors (see Lonca, G. H. et al.
15 *Angewandte Chemie International Edition* **2017**, *56*, 11440-11444).


Hao Xu and coworkers have reported on an iron-catalyzed diazidation reaction of olefins that uses a stoichiometric amount of either a benziodoxole or organic peroxide oxidant (see Yuan, Y.-A. et al. *Angewandte Chemie International Edition* **2016**, *55*, 534; Zhu, H.-T. et al. *Organic Process Research & Development* **2017**, *21*, 2068; and Shen, S.-J. et al. *ACS Catalysis* **2018**, *8*,
20 4473). While this reaction scheme advances the art, it still includes the use of metal catalysis.

In the present invention, the azide is typically added in an anti-Markovnikov orientation across the double bond. Thus, this process provides a means to obtain anti-Markovnikov nitrogen-bearing addition products in an environmentally friendly fashion.

In one aspect, a process is provided for the synthesis of an organic azide comprising
25 combining an olefin, a silyl azide, a hydrogen bond donor, and an organic promoter such that an organic azide is formed. In another aspect, a process is provided for the synthesis of an organic azide of Formula III comprising mixing an olefin of Formula I, a silylazide of Formula II, a hydrogen bond donor, and an organic promoter such that an organic azide of III is formed. In another aspect, a process for the synthesis of an organic azide is provided as illustrated in Scheme

1:

Scheme 1



wherein:

R¹ and R² are independently selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein each of R¹ and R² that is not hydrogen may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷;


wherein at least one of R¹ and R² is not hydrogen;

R³ is selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein R³ other than hydrogen may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷; or

R¹ and R² or R² and R³ are taken together with the carbons to which they are attached to form a cycloalkyl ring or an heterocycloalkyl ring, wherein each cycloalkyl or heterocycloalkyl ring can be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷;

R⁴ is independently selected at each occurrence from alkyl and cycloalkyl;

the organic promoter is selected from:



R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

m is 1, 2, 3, or 4;

5 Z is I;

R^6 and $R^{6'}$ are independently selected from $-O(C=O)R^7$, $-O(SO_2)(R^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

15 two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

25 R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group; or

30 R^9 is aryl or heteroaryl, for example phenyl, pyridyl, pyrazinyl, or quinolinyl, wherein R^9 may be optionally substituted with one or more substituents that do not adversely affect the desired

reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; and


the hydrogen bond donor is water and optionally a second hydrogen bond donor selected from formic acid, an alkylcarboxylic acid, a (cycloalkyl)carboxylic acid, a (heteroalkyl)carboxylic acid, a (heterocycloalkyl)carboxylic acid, an arylcarboxylic acid, an (heteroaryl)carboxylic acid, sulfuric acid, an alkylsulfonic acid, a (cycloalkyl)sulfonic acid, a (heteroalkyl)sulfonic acid, a (heterocycloalkyl)sulfonic acid, an arylsulfonic acid, and a (heteroaryl)sulfonic acid, each of which second hydrogen bond donor other than formic acid and sulfuric acid can be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one aspect, the organic azide formed by the process shown in Scheme 1 produces the anti-Markovnikov addition product or comprises at least about 50% or more of the anti-Markovnikov addition product.

In another aspect, a process is provided for the synthesis of azide-containing oligomers or polymers from simple olefin starting materials. The azide-substituted oligomeric or polymeric compounds that are formed by this process are useful in the synthesis of new materials, such as new polymers for use in medical devices, or in bioconjugation reactions that may lead to new drug delivery methods, for example biologic-polymer-drug conjugates. This oligomerization or polymerization method allows for the preparation of these materials without metal contamination, again allowing ready use in biological systems without concern for toxic contamination.

In another aspect, a process is provided for the synthesis of an azide-containing oligomer or polymer comprising mixing an olefin, a silylazide, a hydrogen bond donor, and an organic promoter, wherein the olefin is substituted with at least one electron withdrawing group, such that an azide-containing oligomer or polymer is formed. In another aspect, a process is provided for the synthesis of an oligomer or polymer of Formula V comprising mixing an olefin of Formula IV, a silyl azide of Formula II, an organic promoter, and a hydrogen bond donor such that an oligomer or polymer of Formula V is formed. In another aspect, a process for the synthesis of an azide-containing oligomer or polymer is provided as illustrated in Scheme 2:

Scheme 2



wherein R⁴, R⁷, the organic promoter, and the hydrogen bond donor are as defined above;

R¹⁰, R¹¹, and R¹² are independently selected from hydrogen, halogen, cyano, $-(C=O)R^7$,
 5 $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, or heteroaryl,
 wherein each of R¹⁰, R¹¹, and R¹² other than hydrogen, halogen, or cyano may be optionally
 substituted with one or more substituents that do not adversely affect the desired reaction, for
 example a substituent selected from oxo, halo, cyano, azido, nitro, R⁷, $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$,
 $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and
 10 $-N(R^7)(C=O)OR^7$; or

R¹⁰ and R¹¹ or R¹¹ and R¹² may be brought together with the carbons to which they are
 attached to form a cycloalkyl ring or a heterocycloalkyl ring, each of which cycloalkyl or
 heterocycloalkyl ring may be optionally substituted with one or more substituents that do not
 adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano,
 15 azido, nitro, R⁷, $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$,
 $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

or in an alternative embodiment, R¹⁰ and R¹¹ may be brought together with the carbons to
 which they are attached to form a cycloalkyl ring or a heterocycloalkyl ring, each of which
 cycloalkyl or heterocycloalkyl ring may be optionally substituted with one or more substituents
 20 that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo,
 cyano, azido, nitro, R⁷, $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$,
 $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

R¹³ is selected from cyano, nitro, $-(C=O)R^{7a}$, $-(C=O)OR^{7a}$, and $-(C=O)N(R^{7a})(R^{7b})$;

R^{7a} and R^{7b} are independently selected at each occurrence from hydrogen, alkyl, aryl,
 25 heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^{7a} and R^{7b}
 other than hydrogen may be optionally substituted with one or more substituents that do not
 adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl,

cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

R^{7a} and R^{7b} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

R^{10} and R^{7a} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; and

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.

In some aspects, the olefin is a terminal olefin. In other aspects, the olefin is an asymmetric internal olefin. In other aspects, the olefin is a trisubstituted olefin. In some embodiments, for example those represented in Scheme 2, the olefin contains an electron-withdrawing substituent.


In one aspect, the hydrogen bond donor is water. In another aspect, the hydrogen bond donor is water and a second hydrogen bond donor. In one embodiment, the second hydrogen bond donor is trifluoroacetic acid. In some embodiments, the hydrogen bond donor is a chiral hydrogen bond donor.

In another aspect, the process described herein is carried out in an organic solvent, a mixture of water and an organic solvent, or a mixture of two or more organic solvents. Exemplary solvents include acetone, ethyl acetate (EtOAc), dichloromethane (CH_2Cl_2), acetonitrile (MeCN), 1,2-dichloroethane (DCE), nitromethane, hexanes, pentane, toluene, benzene, petroleum ether, 2-butanone, chlorobenzene, chloroform ($CHCl_3$), cyclohexane, heptane, *o*-xylene, *m*-xylene, *p*-xylene, and combinations thereof. In one embodiment, the solvent is selected from ethyl acetate (EtOAc), dichloromethane (CH_2Cl_2), or chloroform ($CHCl_3$). In one embodiment, the solvent is

ethyl acetate (EtOAc). In one embodiment, the solvent is dichloromethane (CH₂Cl₂). In one embodiment, the solvent is chloroform (CHCl₃).

In another aspect, a compound used in or formed by the processes described herein can have at least one isotopic substitution. For example, a compound used in or formed by the processes described herein can have at least one deuterium atom. The inclusion of deuterium can affect the rate of a reaction or the stability of the final product, among other things. If the product is a pharmaceutical agent, substitution with deuterium can be used in metabolic profiling. In one non-limiting embodiment, a process is provided for the synthesis of a beta-deuteroalkyl azide of Formula VI as illustrated in Scheme 3:

Scheme 3




wherein R¹, R², R³, R⁴, and the organic promoter are defined as above; and

the deuterium bond donor consists of deuterium oxide and optionally a deuterated acid selected from trifluoroacetic acid-d, acetic acid-d₄, trifluoromethanesulfonic acid-d, methanesulfonic acid-d₄, and formic acid-d₂. In one embodiment, the deuterium is completely incorporated into the product of Formula VIII. In another embodiment, the deuterium is partially incorporated into the product of Formula VIII, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated. In some embodiments, a mixture of deuterium oxide and water is used instead of pure deuterium oxide in the reaction shown in Scheme 3.



In another non-limiting embodiment, the process is provided for the synthesis of a deuterated azide-containing oligomer or polymer of Formula XI as illustrated in Scheme 4:

Scheme 4



Wherein R^4 , R^{10} , R^{11} , R^{12} , R^{13} , n , the organic promoter, and the deuterium bond donor are defined as above. In one embodiment, the deuterium is completely incorporated into the product of Formula XI. In another embodiment, the deuterium is partially incorporated into the product of Formula XI, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated. In some embodiments, a mixture of deuterium oxide and water is used instead of pure deuterium oxide in the reaction shown in Scheme 4.

In another aspect, compounds are provided of Formula VII or Formula VIII:



wherein R^4 , R^5 , R^7 , Z , and m are defined as above; and

R^{14} and $R^{14'}$ are selected from $-O(C=O)R^7$ and $-O(SO_2)(R^7)$.

In another aspect, processes are also provided for the use of the azide-containing product of the inventive process described herein with an alkyne to make a 1,2,3-triazole, for example using an azide-alkyne cycloaddition, in the presence or absence of copper. In one example, a ligand can be added to a biomolecule via the reaction described herein to create an organic azide derivative of an unsaturated starting material, which is then reacted with an alkyne-modified biomolecule. An organic azide formed from an olefin using the processes described herein can

be conjugated to an alkyne-containing modified biomolecule using an azide-alkyne cycloaddition reaction.

In another aspect, processes are also provided for the use of the azide-containing product of the inventive process described herein with an alkyne to make a 1,2,3-triazole, for example using an azide-alkyne cycloaddition, in the presence or absence of copper. In one example, a ligand can be added to a biomolecule via the reaction described herein to create an organic azide derivative of an unsaturated starting material, which is then reacted with an alkyne-modified biomolecule. An organic azide formed from an olefin using the processes described herein can be conjugated to an alkyne-containing modified biomolecule using an azide-alkyne cycloaddition reaction.

In one aspect, a process for the conjugation of an organic ligand molecule to a modified biomolecule is provided, wherein the organic ligand molecule is an olefin and the modified biomolecule contains an alkynyl group, is provided comprising:

(a) converting the alkenyl group of the organic ligand molecule to an azidoalkyl group using one of the processes described herein;

(b) optionally purifying the organic ligand molecule; and

(c) reacting the azido alkyl group of the organic ligand molecule with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the organic ligand molecule to the modified biomolecule.

In another aspect, a process for the conjugation of an organic ligand molecule to a modified biomolecule is provided, wherein the organic molecule ligand is an alkene and the modified biomolecule contains an alkynyl group, is provided comprising:

(a) converting the alkenyl group of the organic ligand molecule to an azidoalkyl group using the reaction shown in Scheme 1;

(b) optionally purifying the organic ligand molecule; and

(c) reacting the azidoalkyl group of the organic ligand molecule with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the organic ligand molecule to the modified biomolecule.

In another aspect, a process for the conjugation of an azide-containing oligomer or polymer formed from an organic molecule containing an alkenyl group to a modified biomolecule, wherein the modified biomolecule contains an alkynyl group, is provided comprising:

(a) converting the alkenyl-containing organic molecule to an azide-containing oligomer or polymer using the reaction shown in Scheme 2;

(b) optionally purifying the azide-containing oligomer or polymer; and

(c) reacting the azide group of the oligomer or polymer with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the oligomer or polymer to the modified biomolecule.

The biomolecule can be, in non-limiting embodiments, a protein, peptide, a nucleoside, nucleotide, polynucleotide, such as a polydeoxyribonucleotide or a polyribonucleotide, antibody, hormone, enzyme, structural protein, aptamer, m-RNA, cDNA, cell, including a lymphocyte, signaling agent, a sugar, a monosaccharide or polysaccharide, or a lipid or lipid-like molecule. The organic molecule may be a substrate, an inhibitor, a drug, a mediator of signaling, a fluorescent probe, or any other organic compound that has or can be modified to have an olefin-containing group that may be useful to conjugate with a biomolecule for any purpose. Step (c) in any embodiments of the bioconjugation process can be performed ex vivo, in vitro, or in vivo depending on the desired application.

Non-limiting aspects of the present invention include:

- 1) A process for the synthesis of an organic azide of Formula III by mixing an olefin of Formula I, a silyl azide of Formula II, an organic promoter, and a hydrogen bond donor until the organic azide product of Formula III is formed;
- 2) A process for the synthesis of an azide-containing oligomer or polymer of Formula V by mixing an olefin of Formula IV, a silyl azide of Formula II, an organic promoter, and a hydrogen bond donor until the azide-containing oligomer or polymer of Formula V is formed;
- 3) A process for the synthesis of a beta-deuteroalkyl azide of Formula VI by mixing an olefin of Formula I, a silyl azide of Formula II, an organic promoter, and a deuterium bond donor until the deuterated azide product of Formula VI is formed;
- 4) A process for the synthesis of a deuterated azide-containing oligomer or polymer of Formula XI by mixing an olefin of IV, a silyl azide of Formula II, an organic promoter, and a deuterium bond donor until the azide-containing oligomer or polymer of Formula XI is formed;
- 5) A compound of Formula VII or Formula VIII;
- 6) A composition comprising:
 - a) a silyl azide of Formula II;

- b) an organic promoter of Formula IX or Formula X;
 - c) water; and
 - d) optionally a second hydrogen bond donor;
- 7) A composition comprising:
- 5 a) a silyl azide of Formula II;
- b) an organic promoter of Formula IX or Formula X;
 - c) an olefin of Formula I;
 - d) water; and
 - e) optionally a second hydrogen bond donor;
- 10 8) A composition comprising:
- a) a silyl azide of Formula II;
 - b) an organic promoter of Formula IX or Formula X;
 - c) an olefin of Formula IV;
 - d) water; and
 - 15 e) optionally a second hydrogen bond donor;
- 9) A process for carrying out the conjugation of an olefin-containing organic compound to a biomolecule comprising reacting the product of the process of Scheme 1 with an alkyne-modified biomolecule to get a 1,2,3-triazole linked conjugate;
- 10) A process for carrying out the conjugation of an olefin-containing organic compound to a biomolecule comprising reacting the product of the process of Scheme 2 with an alkyne-modified biomolecule to get a 1,2,3-triazole linked conjugate; and
- 20 11) A kit comprising:
- a) a first composition containing a silyl azide of Formula III and optionally a first organic solvent;
 - 25 b) a second composition comprising a benziodoxole of Formula IV and optionally a second organic solvent; and
 - c) a third composition comprising water, optionally a second hydrogen bond donor, and optionally a third organic solvent.

An additional non-limiting aspect of the present invention includes:

- 30 12) A kit comprising:

- a) a first composition containing a silyl azide of Formula III and optionally a first organic solvent;
- b) a second composition comprising a benziodoxole of Formula IX and optionally a second organic solvent; and
- 5 c) a third composition comprising water, optionally a second hydrogen bond donor, and optionally a third organic solvent.

Other embodiments will be clear to the skilled worker after reading the detailed disclosure herein, and all variations are intended to be included as part of the scope of the invention.

10 DETAILED DESCRIPTION OF THE INVENTION

Definitions

Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention belongs.

15 The compounds in any of the Formulas described herein may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, N-oxide, or other isomer, such as a rotamer, as if each is specifically described unless specifically excluded by context.

The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term “or” means “and/or”. Recitation of ranges of values merely intend to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All processes described
20 herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of example, or exemplary language (e.g. “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.

A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, $-(C=O)NH_2$ is attached through the carbon of the keto (C=O) group.
30

“Alkyl” is a branched or straight chain saturated aliphatic hydrocarbon group. In one non-limiting embodiment, the alkyl group contains from about 1 to about 50 carbon atoms, more generally from 1 to about 36 carbon atoms, from 1 to about 12 carbon atoms, from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbon atoms. In certain
5 embodiments, the alkyl is C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅, C₁-C₆, C₁-C₇, C₁-C₈, C₁-C₉, or C₁-C₁₀. For example, the term C₁-C₆alkyl as used herein indicates a straight chain or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these are described as an independent species. For example, the term C₁-C₄alkyl as used herein indicates a straight or
10 branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, and 2,3-dimethylbutane. In some embodiments, the alkyl group is optionally substituted as defined herein.

In one embodiment “alkyl” is a C₁-C₁₀alkyl, C₁-C₉alkyl, C₁-C₈alkyl, C₁-C₇alkyl,
15 C₁-C₆alkyl, C₁-C₅alkyl, C₁-C₄alkyl, C₁-C₃alkyl, or C₁-C₂alkyl.

In one embodiment “alkyl” has one carbon.

In one embodiment “alkyl” has two carbons.

In one embodiment “alkyl” has three carbons.

In one embodiment “alkyl” has four carbons.

20 In one embodiment “alkyl” has five carbons.

In one embodiment “alkyl” has six carbons.

Non-limiting examples of “alkyl” include: methyl, ethyl, propyl, butyl, pentyl, and hexyl.

Additional non-limiting examples of “alkyl” include: isopropyl, isobutyl, isopentyl, and
isoheptyl.

25 Additional non-limiting examples of “alkyl” include: *sec*-butyl, *sec*-pentyl, and *sec*-hexyl.

Additional non-limiting examples of “alkyl” include: *tert*-butyl, *tert*-pentyl, and
tert-hexyl.

Additional non-limiting examples of “alkyl” include: neopentyl, 3-pentyl, and active pentyl.

30 In one embodiment “alkyl” is “substituted alkyl”

“Heteroalkyl” refers to an alkyl group as defined herein that contains at least one heteroatom, for example nitrogen, oxygen, sulfur, phosphorous, boron, or silicon, in place of a carbon atom at a position other than at the point of attachment. In some embodiments, “heteroalkyl” also includes groups that contain unsaturation between the heteroatom and a neighboring carbon in such a manner that results in the formation of a stable moiety, for example a -C=N- moiety.

“Cycloalkyl” is a saturated group containing all carbon rings and from 3 to 50 carbon atoms (“C₃-C₅₀cycloalkyl”) and zero heteroatoms in a monocyclic or polycyclic (e.g. bicyclic or tricyclic) non-aromatic ring system. In some embodiments, a cycloalkyl group has 3 to 14 ring atoms (“C₃-C₁₄cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring atoms (“C₃-C₁₀cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 9 ring atoms (“C₃-C₉cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring atoms (“C₃-C₈cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 7 ring atoms (“C₃-C₇cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring atoms (“C₃-C₆cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring atoms (“C₄-C₆cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring atoms (“C₅-C₆cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring atoms (“C₅-C₁₀cycloalkyl”). Exemplary C₃-C₁₀cycloalkyl groups include, without limitation, cyclopropyl (C₃), cyclobutyl (C₄), cyclopentyl (C₅), cyclohexyl (C₆), cycloheptyl (C₇), cyclooctyl (C₈), cyclononyl (C₉), cyclodecenyl (C₁₀), and the like. In some embodiments, a cycloalkyl group may be a bicyclic alkyl group, for example a spirocyclic alkyl group, a fused bicyclic alkyl group, or a bridged bicyclic alkyl group. In some embodiments, “cycloalkyl” also includes ring systems wherein the cycloalkyl ring, as defined above, is fused with one heterocycloalkyl, aryl, or heteroaryl ring wherein the point of attachment is on the cycloalkyl ring, and in such instances, the number of carbon atoms continue to designate the number of carbons in the cycloalkyl ring system. In some embodiments, the cycloalkyl group is optionally substituted as defined herein.

In one embodiment “cycloalkyl” is a C₃-C₈cycloalkyl, C₃-C₇cycloalkyl, C₃-C₆cycloalkyl, C₃-C₅cycloalkyl, C₃-C₄cycloalkyl, C₄-C₈cycloalkyl, C₅-C₈cycloalkyl, or C₆-C₈cycloalkyl.

In one embodiment “cycloalkyl” has three carbons.

In one embodiment “cycloalkyl” has four carbons.

In one embodiment “cycloalkyl” has five carbons.

In one embodiment “cycloalkyl” has six carbons.

In one embodiment “cycloalkyl” has seven carbons.


In one embodiment “cycloalkyl” has eight carbons.


In one embodiment “cycloalkyl” has nine carbons.

In one embodiment “cycloalkyl” has ten carbons.

5 Non-limiting examples of “cycloalkyl” include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclodecyl.

Additional non-limiting examples of “cycloalkyl” include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the cycloalkyl ring.

For example  is an “cycloalkyl” group.

10 However,  is an “aryl” group.

In one embodiment “cycloalkyl” is a “substituted cycloalkyl”

The term “heterocycloalkyl” refers to a cycloalkyl group as defined herein that contains at least one heteroatom, for example nitrogen, oxygen, sulfur, phosphorous, boron, or silicon, in place of a carbon atom. Heterocycloalkyl groups comprise monocyclic 3-8 membered rings, as well as
15 5-16 membered bicyclic ring systems (which can include bridged, fused, and spiro-fused bicyclic ring systems). It does not include rings containing –O–O–, –O–S–, and –S–S– portions. In some embodiments, “heterocycloalkyl” also includes groups that contain unsaturation between the heteroatom and a neighboring carbon in such a manner that results in the formation of a stable moiety, for example a –C=N– moiety. In some embodiments, “heterocycloalkyl” also includes
20 ring systems wherein the cycloalkyl ring, as defined above, is fused with one cycloalkyl, aryl, or heteroaryl ring wherein the point of attachment is on the heterocycloalkyl ring, and in such instances, the number of atoms continue to designate the number of atoms in the heterocycloalkyl ring system. In some embodiments, the cycloalkyl group is optionally substituted as defined herein. In some embodiments, the heterocycloalkyl group is optionally substituted as defined herein.
25 Examples of heterocycloalkyl groups include saturated 3- to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms; saturated 3- to 6-membered heteromonocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms; and saturated saturated 3- to 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms. Additional examples of heterocycloalkyl groups include aziridiny, oxirany, thiirany, azetidiny,

1,3-diazetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, 2-pyrazolinyl, 2-imidazolinyl, tetrahydrofuranly, 1,3-dioxolanyl, tetrahydrothienyl, piperidinyl, piperazinyl, 1,2-oxathiolanyl, 1,3-oxathiolanyl, tetrahydropyranly, 1,3-dioxanyl, thianyl, 1,3-dithianyl, 1,4-dithianyl, 1,3,5-trithianyl, morpholinyl, thiomorpholinyl, pyrrolizidinyl, indolinyl, isoindolinyl,
 5 decahydroisoquinolinyl, decahydroquinolinyl, 1,2,3,4-tetrahydroquinolinyl, quinuclidinyl, 1-azaadamantanyl, 2-azaadamantanyl, oxepanyl, azocanyl, thiocanyl, 1-oxaspiro[4.5]decanyl, 1,6-dioxaspiro[3.4]octanyl, 1-oxaspiro[4.4]nonanyl, 2-oxa-7-axaspiro[3.5]nonanyl, 1,4-dioxa-7-axaspiro[4.4]nonanyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, dihydrobenzofuranly, and dihydrobenzothienyl.

10 In one embodiment “heterocycloalkyl” refers to a cyclic ring with one nitrogen and 3, 4, 5, 6, 7, or 8 carbon atoms.

In one embodiment “heterocycloalkyl” refers to a cyclic ring with one nitrogen and one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.

15 In one embodiment “heterocycloalkyl” refers to a cyclic ring with two nitrogens and 3, 4, 5, 6, 7, or 8 carbon atoms.

In one embodiment “heterocycloalkyl” refers to a cyclic ring with one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.

In one embodiment “heterocycloalkyl” refers to a cyclic ring with one sulfur and 3, 4, 5, 6, 7, or 8 carbon atoms.


20 Non-limiting examples of “heterocycloalkyl” include aziridine, oxirane, thiirane, azetidine, 1,3-diazetidine, oxetane, and thietane.


Additional non-limiting examples of “heterocycloalkyl” include pyrrolidine, 3-pyrroline, 2-pyrroline, pyrazolidine, and imidazolidine.

25 Additional non-limiting examples of “heterocycloalkyl” include tetrahydrofuran, 1,3-dioxolane, tetrahydrothiophene, 1,2-oxathiolane, and 1,3-oxathiolane.


Additional non-limiting examples of “heterocycloalkyl” include piperidine, piperazine, tetrahydropyran, 1,4-dioxane, thiane, 1,3-dithiane, 1,4-dithiane, morpholine, and thiomorpholine.

30 Additional non-limiting examples of “heterocycloalkyl” include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the heterocyclic ring.


For example,  is a “heterocycloalkyl” group.

However,  is an “aryl” group.


Non-limiting examples of “heterocycloalkyl” also include:




5 Additional non-limiting examples of “heterocycloalkyl” include:




Additional non-limiting examples of “heterocycloalkyl” include:




Non-limiting examples of “heterocycloalkyl” also include:




Non-limiting examples of “heterocycloalkyl” also include:



Additional non-limiting examples of “heterocycloalkyl” include:



15 Additional non-limiting examples of “heterocycloalkyl” include:




In one embodiment “heterocycloalkyl” is “substituted heterocycloalkyl”.


As used herein, “aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) $4n+2$ aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic system (“C₆-C₁₄aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“C₆aryl”; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C₁₀aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C₁₄aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more cycloalkyl or heterocycloalkyl groups wherein the point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. The one or more fused cycloalkyl or heterocycloalkyl groups can be 4 to 7 or 5 to 7-membered cycloalkyl or heterocycloalkyl groups that optionally contain 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, phosphorous, sulfur, silicon, and boron. In one non-limiting embodiment, aryl groups are pendant. An example of a pendant ring is a phenyl group substituted with a phenyl group. In some embodiments, the aryl group is optionally substituted as defined herein.

In one embodiment “aryl” is a 6 carbon aromatic group (phenyl).


In one embodiment “aryl” is a 10 carbon aromatic group (naphthyl).


In one embodiment “aryl” is a 6 carbon aromatic group fused to a heterocycle wherein the point of attachment is the aryl ring. Non-limiting examples of “aryl” include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the aromatic ring.

For example  is an “aryl” group.

However,  is a “heterocycle” group.

In one embodiment “aryl” is a 6 carbon aromatic group fused to a cycloalkyl wherein the point of attachment is the aryl ring. Non-limiting examples of “aryl” include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the aromatic ring.

For example  is an “aryl” group.

However,  is a “cycloalkyl” group.

In one embodiment “aryl” is “substituted aryl”.


The term “heteroaryl” denotes aryl ring systems that contain one or more heteroatoms selected from O, N, and S, wherein the ring nitrogen and sulfur atom(s) are optionally oxidized, and nitrogen atom(s) are optionally quaternized. Examples include, but are not limited to: unsaturated 5- to 6-membered heteromonocyclyl groups containing 1 to 4 nitrogen atoms, such as pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, and 2H-1,2,3-triazolyl]; unsaturated 5- to 6-membered heteromonocyclic groups containing an oxygen group, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5- to 6-membered heteromonocyclic groups containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic groups containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, and oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, and 1,2,5-oxadiazolyl]; and unsaturated 5- to 6-membered heteromonocyclic groups containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl and thiadiazolyl [e.g., 1,3,4-thiadiazolyl and 1,2,5-thiadiazolyl]. “Heteroaryl” also refers to polycyclic aromatic ring systems containing heteroatoms within the ring, for example, 1,4-dihydropyrrolo[3,2-b]pyrrolyl, 1,6-dihydropyrrolo[2,3-b]pyrrolyl, 6H-furo[2,3-b]pyrrolyl, 4H-furo[3,2-b]pyrrolyl, 4H-thieno[3,2-b]pyrrolyl, 6H-thieno[2,3-b]pyrrolyl, indolyl, isoindolyl, indolizynyl, indazolyl, benzimidazolyl, 7-azaindolyl, 6-azaindolyl, 5-azaindolyl, 4-azaindolyl, 7-azaindazolyl, pyrazole[1,5-a]pyrimidinyl, purinyl, benzofuryl, isobenzofuryl, benzo[c]thienyl, benzo[b]thienyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 2,1-benzisothiazolyl, benzoxazolyl, benzthiasolyl, benzo[c][1,2,5]thiadiazolyl, quinolynyl, isoquinolynyl, 4H-quinolizynyl, quinoxalynyl, phthalazinyl, quinazolynyl, cinnolynyl, 1,8-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-b]pyrazinyl,

pyrido[2,3-b]pyrazinyl, pteridinyl, carbazolyl, dibenzofuryl, acridinyl, phenazinyl, phenoxazinyl, phenothiazinyl, and phenoxathiinyl. Additional examples of heteroaryl groups include azepinyl, 1,2-diazepinyl, 1,3-diazepinyl, 1,4-diazepinyl, thiepinyl, 1,4-thiazepinyl, and azocinyl. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocycloalkyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of atoms continue to designate the number of atoms in the heteroaryl ring system. The one or more fused cycloalkyl or heterocycloalkyl groups can be 4 to 7 or 5 to 7-membered cycloalkyl or heterocycloalkyl groups that optionally contain 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, phosphorous, sulfur, silicon, and boron. In one non-limiting embodiment, aryl groups are pendant.

In one embodiment “heteroaryl” is a 5 membered aromatic group containing 1, 2, 3, or 4 nitrogen atoms.


Non-limiting examples of 5 membered “heteroaryl” groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.


Additional non-limiting examples of 5 membered “heteroaryl” groups include:



In one embodiment “heteroaryl” is a 6 membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).

Non-limiting examples of 6 membered “heteroaryl” groups with 1 or 2 nitrogen atoms include:







In one embodiment “heteroaryl” is a 9 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

Non-limiting examples of “heteroaryl” groups that are bicyclic include indole, benzofuran, isindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.


Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:



Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:




Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:



In one embodiment “heteroaryl” is a 10 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

15 Non-limiting examples of “heteroaryl” groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.

Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:



In one embodiment “heteroaryl” is “substituted heteroaryl”

20 The term “optionally substituted” denotes the substitution of a group herein by a moiety that forms a stable molecule and meets the desired purpose of the invention and includes, but is not limited to alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy,

cycloalkoxy, heterocycloalkoxy, aryloxy, heteroaryloxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, heteroarylamino, alkylsulfonamino, arylsulfonamino, alkylimino, arylimino, alkylsulfonimino, arylsulfonimino, hydroxyl, halo, sulfhydryl, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino, guanidine, ureido, cyano, nitro, azido, acyl, thioacyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, alkylsufinyl, haloalkyl, B(OH)₂, phosphate, phosphonate, and haloalkoxy. Such groups may be further substituted, for example with hydroxyl, alkyl, alkoxy, halogen, and amino, in such a manner that results in a stable moiety.

In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with one substituent.

In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with two substituents.

In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with three substituents.

In one embodiment a group described herein that can be substituted with 1, 2, 3, or 4 substituents is substituted with four substituents.

Any compound used in or formed by the processes described herein may form a solvate with solvents (including water). Therefore, in one non-limiting embodiment, the invention includes a solvated form of the compound. The term “solvate” refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Non-limiting examples of solvent are water, ethanol, dimethyl sulfoxide, acetone, and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a compound as described herein and water. Solvates in accordance with this disclosure include those wherein the solvent may be isotopically substituted, e.g. D₂O, d₆-acetone, and d₆-DMSO. A solvate can be in a liquid or solid form.

Any compound used in or formed by the processes described herein may be modified by making inorganic or organic acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical processes. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reactive free base forms of these compounds


with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practical. Salts of the present compounds further include solvates of the compound and the compound salts.

5 Examples of salts as described herein include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The salts described herein include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived
10 from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$
15 where n is 0-4, and the like, or using a different acid that produces the same counterion.

Olefin Reactants of Formula I and Formula IV


The process of the present invention involves an olefin reactant. In some embodiments, the olefin reactant is an asymmetric olefin, i.e., the two substituents attached to one of the olefinic
20 carbons are not the same as the two substituents attached to the other olefinic carbon. In some embodiments, the olefin reactant contains a terminal olefin, i.e., one of the olefinic carbons has two hydrogen atoms, and therefore no carbon atoms, as substituents. In other embodiments, the olefin reactant contains a non-terminal olefin, meaning that each olefinic carbon has at least one non-hydrogen substituent. In some embodiments, the olefin reactant is a tri-substituted olefin
25 containing three non-hydrogen substituents.

In some embodiments, for example embodiments of the process shown in Scheme 1, the olefin reactant is a compound of Formula I:




wherein R^1 , R^2 , and R^3 are defined as above.


Non-limiting examples of olefin reactants of Formula I that may be used in the present process include:




each of which may be optionally substituted with one or more substituents as described herein that do not adversely affect the desired reaction.

Non-limiting examples of olefin reactants of Formula I that may be used in the present process include:






Additional non-limiting examples of olefin reactants of Formula I include




each of which may be optionally substituted with one or more substituents as described herein that do not adversely affect the desired reaction.

In other embodiments, for example embodiments of the process shown in Scheme 2, the olefin reactant is an alkene containing an electron-withdrawing group, for example an enone, an acrolein, an acrylate, an acrylamide, or an acrylonitrile. In some embodiments, the olefin reactant is a compound of Formula IV:




wherein R^{10} , R^{11} , R^{12} , and R^{13} are defined as above.

In one embodiment, the olefin reactant is a compound of Formula IVa:




wherein R^{10} , R^{11} , R^{12} , and R^{7a} are defined as above.

In one embodiment, the olefin reactant is a compound of Formula IVb:




wherein R^{10} , R^{11} , R^{12} , and R^{7a} are defined as above.

In one embodiment, the olefin reactant is a compound of Formula IVc:





wherein R^{10} , R^{11} , R^{12} , R^{7a} , and R^{7b} are defined as above.

In one embodiment, the olefin reactant is a compound of Formula IVd:




wherein R^{10} , R^{11} , and R^{12} are defined as above.


In one embodiment, the olefin reactant is a compound of Formula IVe or Formula IVf:



wherein R^{11} and R^{12} are defined as above.


Non-limiting examples of the olefin reactant of Formula IV include:





each of which may be optionally substituted with one or more substituents as described herein that do not adversely affect the desired reaction.

Additional non-limiting examples of the olefin reactant of Formula IV include:




each of which may be optionally substituted with one or more substituents as described herein that do not adversely affect the desired reaction.

10

Silylazide Reactant of Formula II

The process of the present invention also includes a silylazide reactant. In some embodiments, the silylazide reactant is a trialkylazide. In some embodiments, the silylazide reactant is a compound of Formula II:



R^4 is independently selected at each occurrence from alkyl or cycloalkyl; or two R^4 groups may be brought together with the silicon to which they are attached to form a cycloalkyl ring.

In one embodiment, the silylazide reactant is trimethylsilylazide.


20

In another embodiment, the silylazide reactant is triethylsilylazide.

In another embodiment, the silylazide reactant is (*tert*-butyldimethylsilyl)azide.

Organic Promoters


The process of the present invention also includes an organic promoter. In some
5 embodiments, the organic promoter is a compound of Formula IX or Formula X:



wherein Z is I; and


R^5 , R^6 , $R^{6'}$, R^8 , $R^{8'}$, and m are defined as above.

10 In one embodiment, the organic promoter is a compound of Formula IXa:




wherein R^5 , Z and m are defined as above.

In another embodiment, the organic promoter is a compound of Formula IXb:




15 wherein R^5 , R^7 , Z, and m are defined as above. In preferred embodiments of Formula IXb, R^7 is an electron withdrawing substituent, for example trifluoromethyl or trichloromethyl.

In another embodiment, the organic promoter is a compound of Formula IXc:



wherein R^5 , R^7 , Z, and m are defined as above. In preferred embodiments of Formula IXc, R^7 is an electron withdrawing substituent, for example trifluoromethyl or trichloromethyl.


In another embodiment, the organic promoter is a compound of Formula IXd:




5

wherein R^5 , Z and m are defined as above.

In another embodiment, the organic promoter is a compound of the formula




In another embodiment, the organic promoter is a compound of the formula




10


In another embodiment, the organic promoter is a compound of the formula



In another embodiment, the organic promoter is a compound of the formula




In another embodiment, the organic promoter is a compound of the formula



5

In one embodiment, the organic promoter is a compound of Formula Xa:




wherein R^5 , R^6 , $R^{6'}$, and Z are as defined above; and

o is 1, 2, 3, 4, or 5.


10

In one embodiment, the organic promoter is a compound of Formula Xb:




wherein R^5 , R^7 , Z, and o are defined as above. In preferred embodiment of Formula Xb, R^7 is an electron withdrawing substituent, for example trifluoromethyl or trichloromethyl.

In one embodiment, the organic promoter is a compound of Formula Xc:




5 wherein R^5 , Z, and o are defined as above.


In one embodiment, the organic promoter is a compound of the formula



In one embodiment, the organic promoter is a compound of the formula




10 In another embodiment, a compound is provided of Formula VII:






Wherein R^4 , R^5 , R^{14} , $R^{14'}$, Z, and m are defined as above.

15

Non-limiting examples of compounds of Formula VII include:






wherein Z is I. For example,

is


As the skilled worker can appreciate, the above molecules of Formula VII can be modified to have mixed alkyl groups on the silicon, for example two ethyl groups and one methyl group, and to have substituents on any apparent phenyl group, for example a methyl, methoxy, trifluoromethyl, chloro, or fluoro group.


In another embodiment, a compound is provided of Formula VIII:



Wherein R^4 , R^5 , R^{14} , Z, and m are defined as above.

Non-limiting examples of compounds of Formula VIII include:





As the skilled worker can appreciate, the above molecules of Formula VII can be modified to have mixed alkyl groups on the silicon, for example two ethyl groups and one methyl group, and to have substituents on any apparent phenyl group, for example a methyl, methoxy, trifluoromethyl, chloro, or fluoro group.

Hydrogen Bond Donors

The process of the present invention includes the use of a hydrogen bond donor. In one embodiment, the hydrogen bond donor is water.

In some embodiments, the hydrogen bond donor comprises water and an optional second hydrogen bond donor. In some embodiments, the second hydrogen bond donor is selected from an organic acid or a mineral acid.

In one embodiment, the second hydrogen bond donor is formic acid.

In one embodiment, the second hydrogen bond donor is an alkylcarboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, cycloalkoxy, heterocycloalkoxy, aryloxy, heteroaryloxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, heteroarylamino, alkylsulfonamino, arylsulfonamino, alkylimino, arylimino, alkylsulfonimino, arylsulfonimino, hydroxyl, halo, sulfhydryl, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino, guanidine, ureido, cyano, nitro, azido, acyl, thioacyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, alkylsulfinyl, haloalkyl, B(OH)₂, phosphate, phosphonate, and haloalkoxy. In one embodiment, the second hydrogen bond donor is trifluoroacetic acid.

In one embodiment, the second hydrogen bond donor is a (cycloalkyl)carboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl,

halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heteroalkyl)carboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heterocycloalkyl)carboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is an arylcarboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heteroaryl)carboxylic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is sulfuric acid.

In one embodiment, the second hydrogen bond donor is an alkylsulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy. In one embodiment, the second hydrogen bond donor is methanesulfonic acid. In one embodiment, the second hydrogen bond donor is trifluoromethylsulfonic acid.

In one embodiment, the second hydrogen bond donor is an (cycloalkyl)sulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heteroalkyl)sulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heterocycloalkyl)sulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is an arylsulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the second hydrogen bond donor is a (heteroaryl)sulfonic acid optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxyamino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy.

In one embodiment, the hydrogen bond donor is a chiral hydrogen bond donor. Representative examples of chiral hydrogen bond donors are described in Doyle, A. G. and Jacobsen, E. N. *Chemical Reviews* **2007**, *107*, 5713, incorporated herein by reference in its entirety.

Amounts and Relative Ratios of Reaction Components

The absolute and relative amounts of the various components in the inventive process for making nitrogen-containing organic compounds can vary as desired to achieve the desired goal.

In some embodiments, the benziodoxole is typically present in an amount between about 5 and about 50 mol % relative to the amount of olefin reactant. In one embodiment, the benziodoxole is present in an amount between about 5 and about 30 mol % relative to the amount of olefin reactant. In another embodiment, the benziodoxole is present in an amount between about 7 and about 20 mol % relative to the amount of olefin reactant. In one embodiment, the benziodoxole is present in at least about 5 mol %, at least about 6 mol %, at least about 7 mol %, at least about 8 mol %, at least about 9 mol %, at least about 10 mol %, at least about 15 mol %, at least about 20 mol %, at least about 25 mol %, at least about 30 mol %, at least about 35 mol %, at least about 40 mol %, or at least about 50 mol % relative to the amount of olefin reactant.

In some embodiments, the silylazide is typically present in an amount between about 1.8 and about 3.0 equivalents relative to the amount of olefin reactant. In one embodiment, the silylazide is present in an amount between about 2.0 and about 2.5 equivalents relative to the amount of olefin reactant. In one embodiment, the silylazide is present in at least about 1.8 equivalents, 1.9 equivalents, 2.0 equivalents, 2.1 equivalents, 2.2 equivalents, 2.3 equivalents, 2.4 equivalents, 2.5 equivalents, 2.6 equivalents, 2.7 equivalents, 2.8 equivalents, 2.9 equivalents, or 3.0 equivalents relative to the amount of olefin reactant. In one embodiment, the silylazide is present in an amount at least about the sum of the equivalents of the hydrogen bond donor and twice the equivalents of the benziodoxole.

In embodiments where water is the sole hydrogen bond donor, water is typically present in an amount between about 0.6 to about 1.5 equivalents relative to the amount of olefin reactant. In some embodiments, water is present in an amount between about 0.8 to about 1.2 equivalents relative to the amount of olefin reactant. In some embodiment, water is present in at least about 0.6 equivalents, 0.7 equivalents, 0.8 equivalents, 0.9 equivalents, 1.0 equivalents, 1.1 equivalents, 1.2 equivalents, 1.3 equivalents, 1.4 equivalents, or 1.5 equivalents relative to the amount of olefin reactant.

In embodiments where water is used in combination with a second hydrogen bond donor, the sum of the equivalents of water and the equivalents of the second hydrogen bond donor is typically between about 0.8 and about 1.2 relative to the amount of olefin reactant. In some

embodiments, between about 0.6 and 0.8 equivalents of water and between about 0.2 and 0.6 equivalents of the second hydrogen bond donor are used. In one embodiment, about 0.6 equivalents of water and about 0.2 equivalents of the second hydrogen bond donor are used. In one embodiment, about 0.7 equivalents of water and about 0.2 equivalents of the second hydrogen bond donor are used. In one embodiment, about 0.8 equivalents of water and about 0.2 equivalents of the second hydrogen bond donor are used. In one embodiment, about 0.6 equivalents of water and about 0.6 equivalents of the second hydrogen bond donor are used.


Azide Products of Formula III and Formula IV

The processes of the present invention produce an organic azide product or an azide-containing oligomer or polymer product. In the hydroazidation reaction, the anti-Markovnikov product is the organic azide that results when the azido group attaches to the less substituted of the olefinic carbons. Thus when the olefin reactant is a terminal olefin, the anti-Markovnikov product is a primary organic azide.

In some embodiments, the product is substantially or exclusively the anti-Markovnikov product. In some embodiments, the product is a mixture of anti-Markovnikov and Markovnikov products, with the majority in the anti-Markovnikov orientation. In other embodiments, the anti-Markovnikov to Markovnikov orientation is in a ratio within the range of about 1:2 to 100:1, or within about 1:1 to 50:1. For example, the ratio of anti-Markovnikov to Markovnikov products is at at least about 1:1.5, at least about 1:1, at least about 2:1, at least about 3:1, at least about 4:1, at least about 5:1, at least about 10:1, at least about 20:1, at least about 50:1, or more.

Furthermore, in some embodiments the crude yield of anti-Markovnikov product (i.e. prior to purification) is at least about 50% (based on the amount of olefin reactant at the beginning of the reaction), at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or greater.


In some embodiments, for example the reaction shown in Scheme 1, the organic azide product is a compound of Formula III:



wherein R^1 , R^2 , and R^3 are defined as above.

In some embodiments, a product of Formula III is formed upon subjecting an olefin reactant of Formula I to the processes described herein, for example the reaction shown in Scheme 1.

In other embodiments, for example the reaction shown in Scheme 2, the product is an azide-containing oligomer or polymer of Formula V:



wherein R^{10} , R^{11} , R^{12} , R^{13} , and n are defined as above.

In some embodiments, for example the reaction shown in Scheme 2, the product is a mixture of compounds of Formula V having a range of values of n . For example, the product is a mixture of compounds of Formula V wherein n is from 1 to 25, from 5 to 20, from 6, to 19, from 8 to 15, or from 10 to 12. In some embodiment, the product is a mixture of compounds of Formula V wherein n is from 10 to 20, from 11 to 20, from 12 to 20, from 13 to 20, from 14 to 20, from 15 to 20, from 14 to 19, from 15 to 19, from 16 to 19, or from 17 to 18.


In some embodiments, a product of Formula V is formed upon subjecting an olefin of Formula IV to the processes described herein.

Mechanisms and Process Parameters

The process of the present invention may be conveniently carried out in an environmentally friendly non-metal containing one-pot process to create organic azides with anti-Markovnikov selectivity. By “one-pot” is meant that the olefin is combined with all necessary reactants to form the desired product in the same reaction vessel – no transfer and/or isolation of intermediate compounds is necessary.

While not wishing to be bound by any one theory, the mechanism for some embodiments of the present invention, for example the reaction shown in Scheme 1 wherein water is hydrogen bond donor, may be similar to that shown in Scheme 5:


Scheme 5



Reaction of the benziodoxole **A** with the silylazide provides a transient iodine(III) diazide species **B** which subsequently reacts with the olefin to form a beta-azidoalkyl radical species **C**. This species is then trapped by hydrazoic acid, formed by reaction of the silylazide and the hydrogen bond donor, to yield the desired organic azide product.

Also not wishing to be bound by any one theory, the mechanism for other embodiments of the present invention, for example the reaction shown in Scheme 1 wherein water and trifluoroacetic acid are the hydrogen bond donor, may be similar to that shown in Scheme 6:

Scheme 6




- 5 Reaction of trimethylsilylazide with water and trifluoroacetic acid provides trimethylsilyl trifluoroacetate and hydrazoic acid. Reaction of trimethylsilyl trifluoroacetate with the benziodoxole provides the trifluoroacetylated intermediate **A**, which may either be converted into intermediate **B** upon reaction with trimethylsilylazide or may form intermediate **C** upon reaction with another equivalent of trimethylsilyl trifluoroacetate. Intermediate **B** may equilibrate to
- 10 intermediate **C** by reaction with trimethylsilyl trifluoroacetate, and intermediate **C** may equilibrate with intermediate **B** by reaction with trimethylsilylazide. Intermediate **B** subsequently reacts with the olefin to form a beta-azido radical species. This radical species is then trapped by hydrazoic acid that was previously formed to yield the desired organic azide product.

Also not wishing to be bound by any one theory, the mechanism for other embodiments of the present invention, for example the reaction shown in Scheme 1 wherein water and trifluoroacetic acid are the hydrogen bond donor and 3-oxo-1 λ^3 -benzo[d][1,2]iodaoxol-1(3*H*)-yl 2,2,2-trifluoroacetate is used as the organic promoter, may be similar to that shown in Scheme 7:

5

Scheme 7



Reaction of trimethylsilylazide with water and trifluoroacetic acid provides trimethylsilyl trifluoroacetate and hydrazoic acid. The benziodoxole **A** may subsequently be converted to either intermediate **B** on reaction with trimethylsilylazide or intermediate **C** upon reaction reaction with trimethylsilyl trifluoroacetate. Intermediate **B** may equilibrate to intermediate **C** by reaction with trimethylsilyl trifluoroacetate, and intermediate **C** may equilibrate with intermediate **B** by reaction with trimethylsilylazide. Intermediate **B** subsequently reacts with the olefin to form a beta-azido radical species. This radical species is then trapped by hydrazoic acid that was previously formed to yield the desired organic azide product.

Any organic solvents may be used in this process that achieves the desired result. Exemplary solvents include acetone, ethyl acetate (EtOAc), dichloromethane(CH_2Cl_2), acetonitrile (MeCN), 1,2-dichloroethane (DCE), nitromethane, hexanes, pentane, toluene, benzene,

petroleum ether, 2-butanone, chlorobenzene, chloroform (CHCl_3), cyclohexane, heptane, *o*-xylene, *m*-xylene, *p*-xylene, and combinations thereof. In one embodiment, the solvent is selected from ethyl acetate (EtOAc), dichloromethane (CH_2Cl_2), or chloroform (CHCl_3). In one embodiment, the solvent is ethyl acetate (EtOAc). In one embodiment, the solvent is dichloromethane (CH_2Cl_2).

5 In one embodiment, the solvent is chloroform (CHCl_3).

In one aspect, the process is typically performed in an organic solvent at a concentration of the olefin reactant if at least about 1.0 molar. In some embodiments, the reaction is performed at an olefin reactant concentration between about 1.0 molar and about 2.3 molar. In some
10 embodiments, the reaction is performed at a concentration of the olefin reactant of at least about 1.0 molar, at least about 1.1 molar, at least about 1.2 molar, at least about 1.3 molar, at least about 1.4 molar, at least about 1.5 molar, at least about 1.6 molar, at least about 1.7 molar, at least about 1.8 molar, at least about 1.9 molar, at least about 2.0 molar, at least about 2.1 molar, at least about 2.2 molar, at least about 2.3 molar, or more.

The processes of interest are typically performed at room temperature, i.e. a temperature
15 between about 20 °C and 25 °C, but may be performed at a lower temperature if deemed necessary, i.e. at a temperature of no less than about 4 °C, no less than about 5 °C, no less than about 10 °C, no less than about 15 °C, or no less than about 20 °C.

In some embodiments, the processes of interest may further include appropriate purification and isolation steps to remove impurities and reactants from the product organic azide.
20 Furthermore, when the product contains a mixture of anti-Markovnikov and Markovnikov products, the product may be purified to remove the undesired addition product.

In some embodiments, the processes of interest are suitable for preparation of organic azides on any desired scale, including preparatory/research scale and industrial scale. Thus, the reaction vessel in which the processes are carried out may be any convenient size, such as from
25 microliter scale to multi-liter (at least about 5, 10, 100 liters, or greater) scale.

Reaction times and reaction conditions (e.g., temperature, atmosphere, etc.) will vary and may be determined by reference to the examples and disclosure provided herein, as well as routine experimentation and consultation of the relevant literature when necessary. Typical reaction times are at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, at
30 least about 4 hours, at least about 5 hours, at least about 6 hours, or longer. In some embodiments, the processes described herein are run under such conditions so as to achieve the desired result.

Isotopic Substitutions and Deuterium Incorporation Processes

The process of the present invention can be carried out with isotopic, typically deuterated, compounds or solvents. For example, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, the organic promoter, or the hydrogen bond donor, may be selected to have at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e. enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e. the same number of protons but a different number of neutrons.

Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{18}F , ^{31}P , ^{32}P , ^{35}S , ^{36}Cl , and ^{125}I , respectively. In one non-limiting embodiment, the product azide is used to produce an isotopically labeled compound that is employed in metabolic studies (with for example ^{14}C), reaction kinetic studies (with for example ^2H or ^3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computer tomography (SPECT) including drug or substrate tissue distribution assays. In particular, an ^{18}F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds produced using this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

By way of general example and without limitation, isotopes of hydrogen, for example, deuterium (^2H) and tritium (^3H) may be used anywhere in described structures that achieves the desired result. Alternatively or in addition, isotopes of carbon, e.g., ^{13}C and ^{14}C , may be used.

Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 90, 95, or 99% or more enriched in an isotope at any location of interest. In one non-limiting embodiment, deuterium is 90, 95%, or 99% enriched at a desired location.

In one non-limiting embodiment, the substitution of one or more hydrogen atoms for a deuterium atom can be provided in any one of Formula I, Formula II, Formula III, Formula IV,

Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, or Formula XI. In one non-limiting embodiment, the substitution of a hydrogen atom for a deuterium occurs within a group selected from R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^6' , R^7 , R^{7a} , R^{7b} , R^{7c} , R^8 , $R^{8'}$, R^9 , R^{10} , R^{11} , R^{12} , and R^{13} . For example, when any of the groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in non-limiting embodiments, CDH_2 , CD_2H , CD_3 , CH_2CD_3 , CD_2CD_3 , $CHDCH_2D$, CH_2CD_3 , $CHDCHD_2$, $OCDH_2$, OCD_2H , OCD_3 , etc.). In certain other embodiments, when two substituents are combined to form a cycle the unsubstituted carbons may be deuterated.

In one embodiment, a process is provided for the synthesis of a beta-deuteroalkyl azide of Formula VI as illustrated in Scheme 3 above, wherein R^1 , R^2 , R^3 , R^4 , and the organic promoter are defined as above; and the deuterium bond donor consists of deuterium oxide and optionally a deuterated acid selected from trifluoroacetic acid-d, acetic acid-d₄, trifluoromethanesulfonic acid-d, methanesulfonic acid-d₄, and formic acid-d₂. In one embodiment, the deuterium is 100% incorporated into the product of Formula VI. In another embodiment, the deuterium is partially incorporated into the product of Formula VI, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated.

In one embodiment, a process is provided for the synthesis of deuterated azide-containing oligomer or polymer of Formula XI as illustrated in Scheme 4 above, wherein R^4 , R^{10} , R^{11} , R^{12} , R^{13} , and the organic promoter are defined as above; and the deuterium bond donor consists of deuterium oxide and optionally a deuterated acid selected from trifluoroacetic acid-d, acetic acid-d₄, trifluoromethanesulfonic acid-d, methanesulfonic acid-d₄, and formic acid-d₂. In one embodiment, the deuterium is 100% incorporated into the product of Formula XI. In another embodiment, the deuterium is partially incorporated into the product of Formula XI, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated.


Subsequent Transformations of the Organic Azide Products

An organic azide as formed by the present process may be the final desired product, or it may be used as an intermediate through one or more additional reactions to provide a final desired nitrogen-containing product. The reactions of organic azides have been extensively studied, the results of which are summarized in several reviews (see Brase, S. et al. *Angewandte Chemie*

International Edition **2005**, 44, 5188; Huang, D. and Yan, G. *Adv. Synth. Catal.* **2017**, 359, 1600-1619; and Scriven, E. F. V. and Turnbull, K. *Chem. Rev.* **1988**, 88, 297-368; each of which is incorporated herein by reference in its entirety). Thus in one embodiment, the process further comprises a subsequent step for transformation of the formed organic azide product. Non-limiting
 5 representative examples of possible transformations of the organic azide products are provided below.


An organic azide may be reacted with an alkyne in the presence of a metal catalyst to provide a triazole (see Tornøe, C. W. et al. *Journal of Organic Chemistry* **2002**, 67, 3057; and Rostovtsev, V. V. et al. *Angewandte Chemie International Edition* **2002**, 41, 2596). A
 10 representative example of this reaction is provided in Scheme 8 wherein R^A is alkyl optionally substituted with aryl and R^B is alkyl optionally substituted alkoxy, aryloxy, or aryl. In an alternative embodiment, R^A and R^B are independently any variable defined herein.

Scheme 8



An organic azide may be converted to thermally, photochemically, or with a metal catalyst into a reactive nitrene intermediate that may subsequently undergo a number of transformations such as cycloadditions or C-H insertions (see Dequierez, G. et al. *Angewandte Chemie International Edition* **2012**, 51, 7384 for a review of modern nitrene chemistry). A representative example of
 20 this type of reaction is provided in Scheme 9:


Scheme 9



An organic azide can be reacted with a trialkyl or triaryl phosphine to form an
 25 iminophosphorane (see Gololobov, Y.G. and Kasukhin, L.F. *Tetrahedron* **1992**, 48, 1353). This iminophosphorane intermediate can be reacted with water to form a primary amine or with an electrophile such as a ketone to form an imine. A representative example of these types of reactions is provided in Scheme 10 wherein R is alkyl or aryl, and R^C and R^D are independently

selected from hydrogen and alkyl optionally substituted with aryl. In an alternative embodiment, R, R^C and R^D are independently any variable defined herein.

Scheme 10



5 Bioconjugation Processes

In another aspect, processes are also provided for the conjugation of olefin-containing molecules to biomolecules of interest, i.e. for the covalent linkage of olefin-containing compounds to biomolecules of interest. An organic azide or azide-containing oligomer or polymer formed from an olefin using the processes described herein can be conjugated to an alkyne-containing modified biomolecule using an azide-alkyne cycloaddition reaction.

In one aspect, a process for the conjugation of an organic molecular ligand group to a modified biomolecule, wherein the organic molecular ligand contains an alkenyl group and the modified biomolecule contains an alkynyl group, is provided comprising:

- (a) converting the alkenyl group of the organic molecular ligand to an azidoalkyl group using one of the processes described herein;
- (b) optionally purifying the organic molecular ligand; and
- (c) reacting the azidoalkyl group of the organic molecular ligand with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the organic molecule to the modified biomolecule.

In another aspect, a process for the conjugation of an organic molecular ligand to a modified biomolecule, wherein the organic molecular ligand contains an alkenyl group and the modified biomolecule contains an alkynyl group, is provided comprising:

- (a) converting the alkenyl group of the organic molecular ligand to an azidoalkyl group using the reaction shown in Scheme 1;
- (b) optionally purifying the organic molecular ligand; and

(c) reacting the azidoalkyl group of the organic molecular ligand with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the organic molecule to the modified biomolecule.

In another aspect, a process for the conjugation of an azide-containing oligomer or polymer formed from an organic molecular ligand to a modified biomolecule, wherein the organic molecular ligand contains an alkenyl group and the modified biomolecule contains an alkynyl group, is provided comprising:


(a) converting the alkenyl-containing organic molecular ligand to an azide-containing oligomer or polymer using the reaction shown in Scheme 2;

(b) optionally purifying the azide-containing oligomer or polymer; and

(c) reacting the azide group of the oligomer or polymer with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the oligomer or polymer to the modified biomolecule.

The biomolecule can be a polypeptide including a protein, a polynucleotide such as a polydeoxyribonucleotide or a polyribonucleotide, a monosaccharide or polysaccharide, or a lipid or lipid-like molecule. The organic molecule may be a substrate, an inhibitor, a drug, a fluorescent probe, or any other olefin-containing group that may be useful to conjugate with a biomolecule for any purpose. Step (c) in any embodiments of the bioconjugation process can be performed ex vivo, in vitro, or in vivo depending on the desired application.


In one embodiment, reaction of the azidoalkyl group of the alkynyl group of the modified biomolecule occurs via a copper-catalyzed azide-alkyne cycloaddition (CuAAC) (see Tornøe, C. W. et al. *Journal of Organic Chemistry* **2002**, 67, 3057; and Rostovtsev, V. V. et al. *Angewandte Chemie International Edition* **2002**, 41, 2596, the entireties of which are incorporated herein by reference). The CuAAC reaction leads to selective formation of the 1,4-substituted 1,2,3-triazole product. The CuAAC reaction can be performed over a wide range of temperatures (0-160 °C) and pH values (4-12), and can even be performed in water. Typically sodium ascorbate is used as a reducing agent for the copper catalyst in a 3- to 10-fold excess, but hydrazine and hydroxylamine have also been used. Copper-stabilizing ligands may be also added to prevent unwanted copper-mediated oxidation of any functionality of the biomolecule, for example histidine and arginine residues in a polypeptide. Representative examples of copper-stabilizing ligands as used in bioconjugation applications include:



wherein R^L can be benzyl, tert-butyl, or 3-hydroxypropyl.


Representative examples of the CuAAC reaction and its application in bioconjugation are described in: Bock, V. D. et al. *European Journal of Organic Chemistry* **2006**, 51-68; Hen, C. D. et al. *Pharmaceutical Research* **2008**, 25, 2216-2230; Himo, F. et al. *Journal of the American Chemical Society* **2005**, 127, 210-216; Rodionov, V. O. et al. *Angewandte Chemie International Edition* **2005**, 44, 2210-2215; Golas, P. L. et al. *Macromolecules* **2006**, 39, 6451-6457; Hong, V. et al. *Angewandte Chemie International Edition* **2009**, 48, 9879-9883; Besanceney-Webler, C. et al. *Angewandte Chemie International Edition* **2011**, 50, 8051-8056; and Agard, N. J. et al. *Journal of the American Chemical Society* **2004**, 126, 15046-15047; each of which is incorporated herein by reference in its entirety.

In one embodiment, the reaction of the azidoalkyl group of the alkynyl group of the modified biomolecule occurs via a strain-promoted azide-alkyne cycloaddition (SPAAC). The alkynyl group as used in the SPAAC reaction is housed within a cyclooctynyl ring. The high degree of ring strain (18 kcal/mol) allows the reaction to proceed under mild conditions with relatively fast reaction times. Solubility of the cyclooctynyl group in water can typically be increased by the inclusion of polyethyleneglycol (PEG) or sulfonate groups along the point of attachment to the biomolecule. The SPAAC reaction typically results in a mixture of 1,4-triazole regioisomers. Representative examples of cyclooctynyl groups that can be used include:



wherein R^E is the biomolecule or a modified derivative thereof.

In some embodiments, a photolabile “caged” cyclooctynyl variant is used. These variants reveal the reactive alkyne functionality upon exposure to 350 nm light, allowing for spatially controlled bioconjugation reactions. A representative example of photoinduced cyclooctynyl release is provided in Scheme 11 below wherein R^F is a substituted or unsubstituted alkyl. In an alternative embodiment, R^F is any variable defined herein.


Scheme 11

Representative examples of the SPAAC reaction and its application in bioconjugation are described in: Agard, N. J. et al. *Journal of the American Chemical Society* **2004**, 126, 15046-15047; Baskin, J. M. et al. *PNAS* **2007**, 104, 16793-16797; Andronov, A. et al. *Synthesis* **2014**, 46, 669-677; Dommerholt, J. et al. *Topic in Current Chemistry* **2016**, 374, 16; Arumugam, S. et al. *Pure and Applied Chemistry* **2013**, 85, 1499-1513; and Manova, R. et al. *Angewandte Chemie International Edition* **2011**, 50, 5428-5430; each of which is incorporated herein by reference in its entirety.

The alkyne group may be installed on the biomolecule in its intact state or may be incorporated into the biomolecule during synthesis or through post translational modification. The functionalization of intact biomolecules to form modified biomolecules as described herein typically occurs by N-hydroxysuccinimide (NHS) mediated amide bond formation with an amine or carboxylic acid functionality on the biomolecule or by substitution of a thiol group on the biomolecule with a maleimide group.

NHS esters are commonly used to functionalize amino groups on biomolecules due to their aqueous compatibility and selectivity for primary amines on lysine residues or at the N-terminus of polypeptides. A representative example of addition of an alkynyl group using an NHS ester is provided in Scheme 12 below:


Scheme 12



wherein R^E is the biomolecule or a modified derivative thereof. In the absence of amino groups, other functional groups such as alcohols and thiols may alternatively be modified.

- 5 Alternatively, carboxylic acid functional groups on the biomolecule can be functionalized via in situ formation of the NHS ester by reaction with NHS and a coupling reagent (for example DCC or EDC) followed by subsequent reaction with an amino-substituted alkyne reagent. A representative example of this type of reaction is provided in Scheme 13 below:

10 Scheme 13




wherein R^E is the biomolecule or a modified derivative thereof. Functionalization reactions involving NHS esters can be run in aqueous buffers at a pH of 7 to 9 for larger biomolecules, but may be run in organic solvents for smaller biomolecules that do not require aqueous solvation.

- 15 The use of amine-containing buffers such as tris or glycine should be avoided except to quench the functionalization reaction upon completion. Additional details about using NHS esters to functionalize biomolecules can be found in Chan, A. O. et al. *Journal of the American Chemical Society* **2012**, *134*, 2589-2598, incorporated herein by reference in its entirety.

- 20 Thiol groups present on biomolecules, for example cysteine residues, may be functionalized with an alkyne group by reaction with a substituted maleimide reagent. A representative example of this type of functionalization is provided in Scheme 14 below:


Scheme 14



wherein R^E is the biomolecule or a modified derivative thereof. Functionalization reactions involving NHS esters can be run in aqueous buffers at pH 6 to 8. At lower pH values, the reaction tends to be slower but to produce more of the thioether product, while at higher pH values the reaction proceeds faster but with higher levels of hydrolysis of the formed product. The use of thiol-containing buffers such as dithiothreitol (DTT) and beta-mercaptoethanol (BME) should be avoided when using this functionalization procedure. Additional details about using maleimides to functionalize biomolecules can be found in: Fontaine, S. D. et al. *Bioconjugate Chemistry* **2015**, 26, 145-152; and Northrup, B. H. et al. *Polymer Chemistry* **2015**, 6, 3415-3430; each of which is incorporated herein by reference in its entirety.


In some embodiments, the alkyne functional group may be incorporated into the sequence of a polypeptide by using an unnatural amino acid (UAA) that contains the alkyne functional group. The alkyne functional group may be placed via site-specific functionalization, wherein a single amino acid in the polypeptide contains the modification, or by residue-specific functionalization, wherein a particular amino acid is replaced quantitatively throughout the polypeptide. Additional details about using UAAs to functionalize biomolecules can be found in: Kim, S. et al. *Bioorganic and Medicinal Chemistry* **2016**, 24, 5816-5822; Maza, J. C. et al. *Bioconjugate Chemistry* **2015**, 26, 1884-1889; Zimmerman, E. S. et al. *Bioconjugate Chemistry* **2014**, 25, 351-361; and Swiderska, K. W. et al. *Bioorganic and Medicinal Chemistry* **2017**, 25, 3685-3693; each of which is herein incorporated by reference in its entirety.

Site-specific functionalization is typically used for small polypeptides using solid phase peptide synthesis. Representative examples of UAAs that may be used during solid phase peptide synthesis to incorporate an alkyne functional group include:




Additional details regarding the incorporation of UAAs into a biomolecule using solid phase peptide synthesis can be found in: Mulder, G. E. et al. *Chemical Communications* **2012**, 48, 10007-10009; Das, S. et al. *Angewandte Chemie International Edition* **2015**, 54, 13219-13224; Empting, M. et al. *Angewandte Chemie International Edition* **2011**, 50, 5207-5211; van Maarseveen, J. H. et al. *Organic Letters* **2005**, 7, 4503-4506; Torres, O. et al. *ChemBioChem* **2008**, 9, 1701-1705; Lim, S. I. et al. *Journal of Controlled Release* **2013**, 170, 219-223; VanBrunt, M. P. et al. *Bioconjugate Chemistry* **2015**, 26, 2249-2260; each of which is incorporated herein by reference in its entirety.

Alternatively, site-specific functionalization can be used for polypeptides that cannot be formed using solid phase peptide synthesis by using an engineered tRNA unique for the target codon in the polypeptide's mRNA sequence. For residue-specific functionalization, UAAs are included in cell growth medium and incorporated into the primary sequence of the expressed polypeptide. Residue-specific functionalization tends to provide heterogeneous incorporation of the UAAs that may result in altered physical and chemical properties of the polypeptide. Representative examples of UAAs that may be used in these approaches to incorporate an alkyne functional group include:



Additional details regarding residue-specific functionalization can be found in: Budisa, N. *Angewandte Chemie International Edition* **2004**, *43*, 6426-6463; and Johnson, J. A. et al. *Current Opinion in Chemical Biology* **2010**, *14*, 774-780; each of which is incorporated herein by reference in its entirety.


If no alterations of the amino acid residues in the polypeptide sequence can be made without detriment to critical side chain interactions, a heterobifunctional linker containing the alkyne functionality and either a carboxylic acid or amine moiety may be placed on either the N-terminus or C-terminus of the peptide, respectively, as the final step of solid phase peptide synthesis. Representative example heterobifunctional linkers that may be used in this type of approach include:




Additional examples of the use of heterobifunctional linkers as described above in bioconjugation include: Sola, L. et al. *Langmuir* **2016**, *32*, 10284-10295; Bayramoglu, G. et al. *Industrial & Engineering Chemistry Research* **2014**, *53*, 4554-4564; Gao, Y. et al. *Industrial & Engineering Chemistry Research* **2014**, *53*, 16777-16784; Hartwell, B. L. et al. *Biomacromolecules* **2017**, *18*, 1893-1907; Nuhn, L. et al. *Angewandte Chemie International Edition* **2013**, *52*, 10652-10656; Gori, A. et al. *Bioconjugate Chemistry* **2016**, *27*, 2669-2677; Goswami, L. N. et al. *Organic & Biomolecular Chemistry* **2013**, *11*, 1116-1126; Gong, H. et al. *Bioconjugate Chemistry* **2016**, *27*, 217-225; van Geel, R. et al. *Bioconjugate Chemistry* **2015**, *26*, 2233-2242; and Anami, Y. et al. *Organic & Biomolecular Chemistry* **2017**, *15*, 5635-5642; each of which is incorporated herein by reference in its entirety.

If the polypeptide of interest is expressed within cells, post-translational modifications that contain an alkyne functional group can be used. The post translational modification may comprise an alkyne-containing modified sugar, modified lipid, or modified isoprenoid derivative. For example, an acetylated modified sugar may be added to growth medium, and subsequent to

internalization, nonspecific hydrolases and esterases remove the acetate groups and release the modified sugar bearing the alkyne group. The modified sugar may subsequently glycosylate proteins of interest, allowing for later conjugation. Representative examples of modified sugars containing alkyne groups that may be used for post-translational modifications include:



Representative examples of modified lipids or isoprenoids containing alkyne groups that may be used for post-translational modifications include:




Additional details regarding the use of post-translational modification to introduce functionality for bioconjugation can be found in: Wang, H. et al. *Natural Chemical Biology* **2017**, *13*, 415-424; Yoon, H. I. et al. *Bioconjugate Chemistry* **2016**, *27*, 927-936; Besancey-Webler, C. et al. *Bioorganic & Medicinal Chemistry Letters* **2011**, *21*, 4989-4992; Dehnert, K. W. et al. *ACS Chemical Biology* **2011**, *6*, 547-552; Hart, C. et al. *Methods in Molecular Biology* **2011**, *698*, 459-484; Zaro, B. W. et al. *PNAS* **2011**, *108*, 8146-8151; Rangan, K. J. et al. *Journal of the American Chemical Society* **2010**, *132*, 10628-10629; Martin, B. R. et al. *Nature Methods* **2009**, *6*, 135-138; Wilson, J. P. et al. *Molecular & Cellular Proteomics* **2011**, *10*, M110.001198; Kho, Y. et al. *PNAS* **2004**, *101*, 12479-12484; Yount, J. S. et al. *Natural Chemical Biology* **2010**, *6*, 610-614; Martin, B. R. et al. *Nature Methods* **2011**, *9*, 84-89; Palsuledesai, C. C. et al. *ACS Chemical Biology* **2016**,

15

20

11, 2820-2828; Degraw, A. J. et al. *Chemical Biology & Drug Design* **2010**, 76, 460-471; and Charron, G. et al. *Molecular BioSystems* **2011**, 7, 67-73; each of which is incorporated herein by reference in its entirety.

In other embodiments, alkyne modified nucleic acids or membrane components may be used to install a reactive handle in actively synthesized DNA, RNA, or cell membranes within a cell. Some representative examples of modified nucleotides that may be incorporated into polynucleotides for bioconjugation include:



A representative example of a modified phospholipid precursor that may be used for cell membrane bioconjugation includes:



Additional details regarding the use of modified nucleotides or membrane components for bioconjugation can be found in: Neef, A. B. et al. *ChemBioChem* **2012**, 13, 1750-1753; Marks, S. I. et al. *Bioconjugate Chemistry* **2011**, 22, 1259-1263; Winz, M. L. et al. *Nucleic Acids Research* **2015**, 43, e110; Sawant, A. A. et al. *Nucleic Acids Research* **2016**, 44, e16; Jao, C. Y. et al. *PNAS* **2009**, 106, 15332-15337; and Taskova, M. et al. *Bioconjugate Chemistry* **2017**, 28, 768-774; each of which is incorporated herein by reference in its entirety.

Additional strategies for bioconjugation and its use in biological applications as can be used in the present invention are described in: Taskova, V. et al. *Bioconjugate Chemistry* **2017**, 28, 768-774; Kim, S. et al. *Bioorganic & Medicinal Chemistry* **2016**, 24, 5816-5822; Kirshenbaum, K. et al. *ChemBioChem* **2002**, 3, 235-237; Laughlin, S. T. and Bertozzi, C. R. *PNAS* **2009**, 106, 12-17; Zheng, T. et al. *Angewandte Chemie* **2011**, 123, 4199-4204; Li, X. et al. *Angewandte Chemie International Edition* **2014**, 53, 7179-7182; Zeglis, B. M. et al. *Bioconjugate Chemistry* **2013**, 24, 1057-1067; Kim, D. W. et al. *Journal of Fluorine Chemistry* **2015**, 28, 142-147; Kulkarni, C. et al. *Bioconjugate Chemistry* **2017**, 28, 1041-1047; Puthenveetil, S. et al. *Bioconjugate Chemistry* **2016**, 27, 1030-1039; and Lee, M. T. et al. *Chemical Science* **2017**, 8, 2056-2060; each of which is incorporated herein by reference in its entirety.

EXPERIMENTAL EXAMPLES OF THE PRESENT INVENTION

General Procedures

All reactions were performed in oven-dried or flame-dried round-bottom flasks and vials. Stainless steel syringes and cannula were used to transfer air- and moisture-sensitive liquids. Flash chromatography was performed using silica gel 60 (230–400 mesh) from Sigma–Aldrich.

Materials

Commercial reagents were purchased from Sigma–Aldrich, Fluka, EM Science, and Lancaster and used as received. All solvents were used after being freshly distilled unless otherwise noted.

Instrumentation


Proton nuclear magnetic resonance (^1H NMR) spectra and carbon nuclear magnetic resonance (^{13}C NMR) spectra were recorded on a Bruker UltraShield–400 (400 MHz) nuclear magnetic resonance spectrometer. Chemical shifts for protons are reported in parts per million downfield from tetramethylsilane and are referenced to the NMR solvent residual peak (CHCl_3 δ 7.26). Chemical shifts for carbons are reported in parts per million downfield from tetramethylsilane and are referenced to the carbon resonances of the NMR solvent (CDCl_3 δ 77.0). Data are represented as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants in Hertz (Hz), and integration. When ^{19}F NMR is used for quantitative purpose (*dr* determination), 30 degrees pulse and a longer delay time

(d1 = 5 s) were employed and the receiver gain was manually set as 32. The mass spectroscopic data were obtained at the Georgia State University mass spectrometry facility using a Micromass Platform II single quadrupole instrument. Infrared (IR) spectra were obtained using a Perkin Elmer Spectrum 100 FT-IR spectrometer. Data are represented as follows: frequency of absorption (cm⁻¹) and absorption strength (s = strong, m = medium, w = weak).

Abbreviations

The following abbreviations are used in the synthetic schemes:


	Boc ₂ O	di- <i>tert</i> -butyl dicarbonate
10	CH ₂ Cl ₂	dichloromethane
	DCC	<i>N,N</i> -dicyclohexylcarbodiimide
	DMAP	4-dimethylaminopyridine
	Et ₂ O	diethyl ether
	EtOAc	ethyl acetate
15	^t PR ₂ NH	diisopropylamine
	MeCN	acetonitrile
	MeI	methyl iodide
	MeOH	methanol
	Ns	4-nitrobenzenesulfonyl
20	TEA	triethylamine
	TEMPO	2,2,6,6,-tetramethyl-1-piperidinyloxy
	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	TIPS	triisopropylsilyl
25	TLC	thin layer chromatography
	Troc	2,2,2-trichloroethoxycarbonyl

Example 1. Synthesis of 1-Azidododecane by Procedure 1


1-Dodecene is commercially available and was distilled before use.

To a flame-dried sealable 2-dram vial equipped with a stir bar were added 1-dodecene (222
 5 μL , 1.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (27 mg, 0.1 mmol, 0.1 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.2 mL) and H_2O (18 μL , 1.0 mmol, 1.0 equiv) were added via syringes. Freshly opened trimethylsilylazide (237 μL , 1.8 mmol, 1.8 equiv) was added to the reaction and the mixture was stirred for 2 h at 22 $^\circ\text{C}$ until the olefin was fully consumed (monitored by TLC). The reaction was
 10 cooled to 0 $^\circ\text{C}$, Hexanes (2 mL) and saturated NaHCO_3 solution (1.5 mL) were added to quench the reaction and to neutralize the residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford 1-
 15 azidododecane as colorless oil (190 mg, 90% yield) which is a known compound (see Hays, D.S. et al *The Journal of Organic Chemistry* **1998**, 63, 2796).


Example 2. Synthesis of 1-Azidododecane by Procedure 2



To a flame-dried sealable 2-dram vial equipped with a stir bar were added 1-dodecene (222 μL , 1.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (19 mg, 0.07 mmol, 0.07 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.2 mL) and H_2O (11 μL , 0.6 mmol, 0.6 equiv) were added via syringes. After the vial was cooled to 0 $^\circ\text{C}$, freshly distilled trimethylsilylazide (237 μL , 1.8 mmol, 1.8 equiv) was added to the reaction followed by the addition of trifluoroacetic acid (TFA) (15 μL , 0.2 mmol, 0.2 equiv). The mixture was warmed up to 22 $^\circ\text{C}$ and kept stirring for 1.5 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 $^\circ\text{C}$, hexanes (2 mL) and saturated NaHCO_3 solution (1.5 mL) were added to quench the reaction and to neutralize the residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford 1-azidododecane as colorless oil (192 mg, 91% yield).

Example 3. Synthesis of 1-Azidododecane by Procedure 3


To a flame-dried sealable 2-dram vial equipped with a stir bar were added 1-dodecene (222 μL , 1.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (19 mg, 0.07 mmol, 0.07 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.2 mL) and trifluoroacetic acid (15 μL , 0.2 mmol, 0.2 equiv) were added via syringes and the mixture was stirred at room temperature for 5 min. During this time, the solution first became homogenous, and then white precipitates formed. H_2O (11 μL , 0.6 mmol, 0.6 equiv) and trimethylsilylazide (239 μL , 1.8 mmol, 1.8 equiv) were added to the reaction and the mixture was stirred at room temperature for 1.5 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 $^\circ\text{C}$. Hexanes (2 mL) and saturated NaHCO_3 solution (1.5 mL) were added to quench the reaction and to neutralize the residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford 1-azidododecane as colorless oil (189 mg, 89% yield).

Example 4. Synthesis of 3-Oxo-1 λ^3 -benzo[d][1,2]iodaoxol-1(3H)-yl 2,2,2-trifluoroacetate

To a flame-dried flask (25 mL) equipped with a stir bar was added 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (1.0 g, 3.8 mmol, 1.0 equiv). After the flask was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (7.6 mL) was added, followed by the addition of trifluoroacetic acid (TFA) (0.35 mL, 4.55 mmol, 1.2 equiv) via syringe. The reaction was stirred for 3 h at 22 °C, during this period, the mixture first became homogenous, and then white precipitates formed. After stirred for 3 h, the precipitate was filtered and washed with CH₂Cl₂ (5 mL × 2), then dried in *in vacuo* to afford 3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl 2,2,2-trifluoroacetate as a white solid (1.12 g, 82% yield, m.p. 212–214 °C).

IR ν_{max} (neat)/cm⁻¹: 3115 (w), 3092 (w), 3066 (w), 1705 (s), 1671 (s), 1589 (m), 1570 (m), 1463 (m), 1443 (m), 1385 (s), 1279 (s), 1244 (s), 1168 (s), 1144 (s), 1108 (s), 856 (s), 826 (s), 780 (s), 753 (s), 731 (s), 696 (m); ¹H NMR (400 MHz, CD₃OD) δ 8.16 (dd, *J* = 7.6, 1.4 Hz, 1H), 8.03–7.95 (m, 1H), 7.87 (d, *J* = 7.8 Hz, 1H), 7.74 (td, *J* = 7.5, 0.9 Hz, 1H); ¹³C NMR (100 MHz, CD₃OD) δ 170.2, 158.3 (q, *J* = 40.1 Hz), 135.1, 131.8, 130.6, 130.5, 126.3, 118.9, 112.3 (q, *J* = 285.0 Hz); ¹⁹F NMR (376 MHz, CD₃OD) δ -77.76.

Example 5. Synthesis of 1-Azidododecane Using Catalytic 3-Oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl 2,2,2-trifluoroacetate




To a flame-dried sealable 2-dram vial equipped with a stir bar were added 1-dodecene (222 μ L, 1.0 mmol, 1.0 equiv) and 3-oxo-1 λ^3 -benzo[*d*][1,2]iodaoxol-1(3*H*)-yl 2,2,2-trifluoroacetate (25 mg, 0.07 mmol, 0.07 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.2 mL) and H₂O (13 μ L, 0.7 mmol, 0.7 equiv) were added via syringes. After the vial was cooled to 0 °C, freshly distilled trimethylsilylazide (237 μ L, 1.8 mmol, 1.8 equiv) was added

to the reaction followed by the addition of trifluoroacetic acid (15 μ L, 0.2 mmol, 0.2 equiv). The mixture was warmed up to 22 $^{\circ}$ C and kept stirring for 2 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 $^{\circ}$ C, Hexanes (2 mL) and saturated NaHCO_3 solution (1.5 mL) were added to quench the reaction and to neutralize the residual hydrazoic acid.

5 The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford 1-azidododecane as colorless oil (190 mg, 90% yield).


10 Example 6. Synthesis of 1-Azido-2-methylnonane



2-Methylnon-1-ene is commercially available and was distilled before use.

The reaction was carried out on a 1.0 mmol scale and Procedure 1 of Example 1 was applied. The crude product was purified through column chromatography (100% hexanes) to afford the
 15 desired product 1-azido-2-methylnonane as a colorless oil (161 mg, 88% yield).


IR ν_{max} (neat)/ cm^{-1} : 2958 (m), 2925 (s), 2856 (m), 2094 (s), 1460 (m), 1380 (m), 1272 (s), 723 (w);
 ^1H NMR (400 MHz, CDCl_3) δ 3.21 (dd, $J = 12.0, 5.9$ Hz, 1H), 3.09 (dd, $J = 12.0, 7.0$ Hz, 1H),
 1.76–1.63 (m, 1H), 1.42–1.19 (m, 12H), 0.95 (d, $J = 6.7$ Hz, 3H), 0.89 (t, $J = 6.8$ Hz, 3H); ^{13}C
 NMR (100 MHz, CDCl_3) δ 57.9, 34.1, 33.5, 31.8, 29.7, 29.2, 26.8, 22.7, 17.7, 14.1; LRMS: m/z
 20 (EI) calcd for $\text{C}_{10}\text{H}_{21}\text{N}^+$, $[\text{M} - \text{N}_2]^+$, 155.2, found 155.2.

Example 7. Synthesis of 4-Azidoctane

(*E*)-Oct-4-ene is commercially available and was distilled before use.

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with several modifications: 0.2 equiv of 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(*1H*)-one and 2.0 equiv of trimethylsilylazide were used; and the reaction was set up at 0 °C and slowly warmed to 22 °C over 0.5 h, then was kept stirring for another 2 h at 22 °C. The crude product was purified through column chromatography (100% hexanes) to afford 4-azidoctane as a colorless oil (110 mg, 71% yield).

IR ν_{max} (neat)/cm⁻¹: 2960 (s), 2934 (s), 2874 (m), 2093 (s), 1466 (m), 1252 (s), 1119 (w), 950 (w), 719 (m); ¹H NMR (400 MHz, CDCl₃) δ 3.37–3.07 (m, 1H), 1.61–1.39 (m, 5H), 1.38–1.21 (m, 5H), 0.99–0.84 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 62.8, 36.5, 34.1, 28.3, 22.5, 19.3, 13.9, 13.8; LRMS: *m/z* (EI) calcd for C₈H₁₇N⁺, [M – N₂]⁺, 127.1, found 127.1.

Example 8. Synthesis of 2-Azidoctane and 3-Azidoctane


(E)-Oct-2-ene is commercially available and was distilled before use.

The reaction was carried out on a 1.0 mmol scale and Procedure 2 of Example 2 was applied.

The crude product was purified through column chromatography (100% hexanes) to afford a 1.4:1 mixture of 2-azidooctane and 3-azidooctane as a colorless oil (113 mg, 73% yield).


5 IR ν_{max} (neat)/ cm^{-1} : 2959 (m), 2931 (s), 2859 (m), 2093 (s), 1458 (m), 1380 (m), 1248 (s), 1050 (w), 902 (w), 726 (w); **2-Azidooctane**: ^1H NMR (400 MHz, CDCl_3) δ 3.49–3.31 (m, 1H), 1.68–1.26 (m, 10H), 1.23 (d, $J = 6.5$ Hz, 3H), 0.92–0.80 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 58.0, 36.2, 31.7, 29.0, 26.0, 22.5, 19.4, 14.0; **3-Azidooctane**: ^1H NMR (400 MHz, CDCl_3) δ 3.27–3.06 (m, 1H), 1.68–1.26 (m, 10H), 0.97 (t, $J = 7.4$ Hz, 3H), 0.92–0.80 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 64.6, 33.9, 31.6, 27.4, 25.8, 22.5, 13.9, 10.4; LRMS: m/z (EI) calcd for $\text{C}_8\text{H}_{17}\text{N}^+$, $[\text{M} - \text{N}_2]^+$, 127.1, found 127.1.

Example 9. Synthesis of 2-Azidobicyclo[2.2.1]heptane



15 Bicyclo[2.2.1]hept-2-ene is commercially available and was used directly without further purification.

The reaction was carried out on a 1.0 mmol scale and Procedure 1 of Example 1 was applied. The crude product was purified through column chromatography (100% hexanes) to afford 2-azidobicyclo[2.2.1]heptane as a colorless oil (96 mg, 70% yield) which is a known compound (see
20 Breton, G. W. et al. *The Journal of Organic Chemistry* **1992**, 57, 6646).

Example 10. Synthesis of (1*R*,3*S*,4*S*)-3-(Azidomethyl)-2,2-dimethylbicyclo[2.2.1]heptane


(+)-Camphene is commercially available and was used directly without further purification.

The reaction was carried out on a 1.0 mmol scale and Procedure 1 of Example 1 was applied.

5 The crude product was purified through column chromatography (100% hexanes) to afford (1*R*,3*S*,4*S*)-3-(azidomethyl)-2,2-dimethylbicyclo[2.2.1]heptane as a colorless oil (158 mg, 88% yield, dr:10:1).

IR ν_{max} (neat)/cm⁻¹: 2955 (s), 2879 (m), 2086 (s), 1464 (m), 1366 (m), 1264 (s), 1116 (w), 895 (m);
 1H NMR (400 MHz, CDCl₃) δ 3.25 (d, *J* = 8.2 Hz, 2H), 2.26 (s, 1H), 1.77 (s, 1H), 1.66 (dt, *J* =
 10 12.1, 3.8 Hz, 2H), 1.60–1.47 (m, 1H), 1.39–1.25 (m, 3H), 1.22 (d, *J* = 9.9 Hz, 1H), 1.00 (s, 3H),
 0.85 (s, 3H); 13C NMR (100 MHz, CDCl₃) δ 50.0, 49.5, 49.0, 40.7, 37.0 (2 carbon merged), 32.2,
 24.5, 20.7, 20.2; LRMS: *m/z* (EI) calcd for C₁₀H₁₇N⁺, [M – N₂]⁺, 151.1, found 151.1.

The relative stereochemistry was determined by X-ray crystallographic analysis of *N*-
 15 (((1*S*,2*S*,4*R*)-3,3-dimethylbicyclo[2.2.1]heptan-2-yl)methyl)-4-nitrobenzenesulfonamide
 synthesized by the procedure below:




To a flask (25 mL) equipped with a stir bar was added (1*R*,3*S*,4*S*)-3-(azidomethyl)-2,2-
 dimethylbicyclo[2.2.1]heptane (150 mg, 0.84 mmol, 1.0 equiv), H₂O (0.15 mL, 8.37 mmol, 10
 20 equiv) and THF (6 mL). After the flask was evacuated and backfilled twice with N₂, a solution of

triphenylphosphine (262 mg, 1.0 mmol, 1.2 equiv) in THF (2 mL) was added drop-wise at 0 °C. The mixture was warmed up to 22 °C and stirred for 8 h (monitored by TLC until the azide starting material was fully consumed). Subsequently, 4-nitrobenzenesulfonyl chloride (222 mg, 1.0 mmol, 1.2 equiv) in THF (5 mL) and Et₃N (0.17 mL, 1.26 mmol, 1.5 equiv) were added to the above mixture drop-wise at 0 °C. The resulting solution was warmed up to room temperature and kept stirring for additional 2 h. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 6:1) to afford *N*-(((1*S*,2*S*,4*R*)-3,3-dimethylbicyclo[2.2.1]heptan-2-yl)methyl)-4-nitrobenzenesulfonamide as a white solid (235 mg, 83% yield, m.p. 125–127 °C).

IR ν_{max} (neat)/cm⁻¹: 3292 (m), 3108 (w), 2956 (m), 2876 (m), 1529 (s), 1348 (s), 1162 (s), 1094 (m), 853 (m), 735 (s), 686 (m); ¹H NMR (400 MHz, CDCl₃) δ 8.38 (d, *J* = 8.8 Hz, 2H), 8.06 (d, *J* = 8.8 Hz, 2H), 4.34 (t, *J* = 5.7 Hz, 1H), 3.02 (dt, *J* = 12.3, 6.2 Hz, 1H), 2.92 (ddd, *J* = 12.2, 10.1, 5.6 Hz, 1H), 2.12 (s, 1H), 1.75 (s, 1H), 1.61–1.45 (m, 3H), 1.35–1.15 (m, 3H), 1.15–1.02 (m, 1H), 0.94 (s, 3H), 0.78 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.0, 145.8, 128.3, 124.4, 49.9, 48.9, 41.5, 40.0, 37.0, 36.8, 32.3, 24.3, 20.7, 19.9; HRMS (ESI, *m/z*): calcd for C₁₆H₂₂N₂O₄SN⁺, [*M* + Na⁺], 361.1192, found 361.1190.

N-(((1*S*,2*S*,4*R*)-3,3-Dimethylbicyclo[2.2.1]heptan-2-yl)methyl)-4-nitrobenzenesulfonamide was recrystallized from EtOAc/hexanes and analyzed by X-ray crystallography.

Example 11. Synthesis of Azidocyclooctane




(*Z*)-Cyclooctene is commercially available was distilled before use.

The reaction was carried out on a 1.0 mmol scale and Procedure 1 of Example 1 was applied. The crude product was purified through column chromatography (100% hexanes) to afford the azidocyclooctane as a colorless oil (107 mg, 70% yield) which is a known compound (see Waser, J., et al. *Journal of the American Chemical Society* **2006**, 128, 11693).

5

Example 12. Synthesis of (3-Azidopropyl)benzene and (2-Azidopropyl)benzene




Allylbenzene is commercially available and was distilled before use.

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modifications: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one and 2.5 equiv of trimethylsilyl azide were used. The crude product was purified through column chromatography (100% hexanes) to afford a 15:1 mixture of (3-azidopropyl)benzene and (2-azidopropyl)benzene as a colorless oil (119 mg, 74% yield) which are known compounds (see Ngai, M. H. et al. *Chemical Communications* **2010**, 46, 8335; Zhu, Y. et al. *Organic Letters* **2015**, 17, 4702).

15

The structure was additionally confirmed by ^1H and ^{13}C NMR analysis of its derivatives *N*-(3-phenylpropyl)acetamide and *N*-(1-phenylpropan-2-yl)acetamide synthesized by the procedure below:




20

To a 25 mL 2-neck round bottom flask equipped with a stir bar and a three-way adapter was added Pd/C (32 mg, 10 wt. %). After the flask was evacuated and backfilled twice with N₂, a solution of the mixture of (3-azidopropyl)benzene and (2-azidopropyl)benzene (322 mg, 2.0 mmol, 1.0 equiv) in MeOH (10 mL) was added. The mixture was degassed with brief evacuation and backfilled three times with H₂, and then vigorously stirred under H₂ balloon at 22 °C for 5 h (monitored by TLC until the azide starting material was fully consumed). The solution was filtered through a Celite pad and washed with MeOH (10 mL). The combined filtrates were concentrated to afford the crude amine, which was then dissolved in 15 mL THF. Ac₂O (227 μL, 2.4 mmol, 1.2 equiv) and Et₃N (417 μL, 3.0 mmol, 1.5 equiv) were added to the above mixture drop-wise successively at 0 °C. The resulting mixture was warmed up to room temperature and kept stirring for additional 2 h until the amine intermediate was fully consumed (monitored by TLC). After concentration *in vacuo*, the residue was subsequently purified through column chromatography (hexanes/EtOAc: from 20:1 to 2:1) to afford *N*-(3-phenylpropyl)acetamide as a colorless oil (298 mg, 84% yield) along with *N*-(1-phenylpropan-2-yl)acetamide as a colorless oil (21 mg, 6% yield).

***N*-(3-Phenylpropyl)acetamide:** IR ν_{max} (neat)/cm⁻¹: 3284 (w), 1647 (s), 1551 (s), 1496 (m), 1454 (m), 1437 (m), 1368 (m), 1266 (s), 1031 (w), 733 (s), 699 (s); ¹H NMR (400 MHz, CDCl₃) δ 7.28–7.26 (m, 2H), 7.19–7.16 (m, 3H), 5.44 (s, 1H), 3.28 (dd, *J* = 13.2, 6.9 Hz, 2H), 2.69–2.62 (m, 2H), 1.93 (s, 3H), 1.89–1.79 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 141.4, 128.5, 128.3, 126.0, 39.3, 33.3, 31.2, 23.3; HRMS (ESI, *m/z*): calcd for C₁₁H₁₅NONa⁺, [*M* + Na⁺], 200.1046, found 200.1042.

***N*-(1-Phenylpropan-2-yl)acetamide:** IR ν_{max} (neat)/cm⁻¹: 3285 (w), 1651 (s), 1549 (m), 1516 (m), 1454 (m), 1373 (m), 1265 (s), 1031 (w), 732 (s), 701 (s); ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.04 (m, 5H), 5.26 (s, 1H), 4.26 (dp, *J* = 13.6, 6.7 Hz, 1H), 2.83 (dd, *J* = 13.5, 5.7 Hz, 1H), 2.72 (dd, *J* = 13.5, 7.2 Hz, 1H), 1.93 (s, 3H), 1.10 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.2, 137.8, 129.5, 128.4, 126.4, 46.0, 42.3, 23.5, 19.9; HRMS (ESI, *m/z*): calcd for C₁₁H₁₅NONa⁺, [*M* + Na⁺], 200.1046, found 200.1042.

Example 13. Synthesis of (3-Azidopropyl)triisopropylsilane


Allyltriisopropylsilane was prepared using a known procedure (see Murakami, K. et al. *The Journal of Organic Chemistry* **2009**, 74, 1415).

5 The reaction was carried out on a 1.0 mmol scale. Procedure 1 of Example 1 was applied with several modifications: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5 equiv of trimethylsilylazide were used; and the reaction was set up at 0 °C and slowly warmed to 22 °C over 0.5 h, then was kept stirring for another 3 h at 22 °C. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 50:1) to afford (3-
10 azidopropyl)triisopropylsilane as a colorless oil (174 mg, 72% yield).

IR ν_{max} (neat)/cm⁻¹: 2941 (s), 2891 (m), 2866 (s), 2092 (s), 1462 (m), 1242 (m), 1015 (m), 881 (s), 727 (s), 696 (s); ¹H NMR (400 MHz, CDCl₃) δ 3.24 (t, *J* = 6.9 Hz, 2H), 1.76–1.59 (m, 2H), 1.08–1.04 (m, 21H), 0.65–0.60 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 55.0, 24.1, 18.8, 10.9, 6.5; LRMS: *m/z* (EI) calcd for C₁₂H₂₇NSi⁺, [M – N₂]⁺, 213.2, found 213.2.


15

20

Example 14. Synthesis of 3-Azidopropyl Benzoate

Allyl benzoate was prepared using a known procedure (see Cossy, J. et al. *Tetrahedron: Asymmetry* **1999**, *10*, 3859).

- 5 The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with several modifications: 0.3 equiv of 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5 equiv of trimethylsilylazide were used; and allyl benzoate in CH₂Cl₂ (0.2 mL) was slowly added to the reaction over 2 h, then was kept stirring for another 2 h at 22 °C. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford 3-azidopropyl benzoate as a colorless oil (125 mg, 61% yield) which is a known compound (see Baruah, M. and Bols, M. *Synlett* **2002**, *2002*, 1111).
- 10


Example 15. Synthesis of 4-Azidobutyl Benzoate

- 15 But-3-en-1-yl benzoate was prepared using a known procedure (see Bogen, S. et al. *Bioorganic & Medicinal Chemistry Letters* **2008**, *18*, 4219).

The reaction was carried out on a 1.0 mmol scale and Procedure 2 of Example 2 was applied. The crude product was purified through column chromatography (hexanes/EtOAc: 100:1 to 10:1) to afford 4-azidobutyl benzoate as a colorless oil (191 mg, 87% yield) which is a known compound (see Bates, R. W. et al. *Organic Letters* **2009**, *11*, 3706).

5

Example 16. Synthesis of 2,2,2-Trichloroethyl (3-Azidopropyl)carbamate and 2,2,2-Trichloroethyl (2-Azidopropyl)carbamate




2,2,2-Trichloroethyl allylcarbamate was prepared using a known procedure (see Kazuhiro, M. et al. *Bulletin of the Chemical Society of Japan* **1987**, *60*, 1021).

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with several modifications: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one, 3.0 equiv of trimethylsilylazide, and 0.6 equiv of trifluoroacetic acid were used; and the reaction was set up at 0 °C, slowly warmed to 22 °C over 0.5 hours, and was kept stirring for another 4 h at 22 °C. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 5:1) to afford 2,2,2-Trichloroethyl (3-Azidopropyl)carbamate as a colorless oil (157 mg, 57%) along with 2,2,2-Trichloroethyl (2-Azidopropyl)carbamate as a colorless oil (28 mg, 10% yield).

2,2,2-Trichloroethyl (3-Azidopropyl)carbamate: IR ν_{max} (neat)/ cm^{-1} : 3337 (br), 2949 (w), 2094 (s), 1712 (s), 1522 (s), 1453 (m), 1240 (s), 1144 (s), 1036 (m), 814 (s), 721 (s); ^1H NMR (400 MHz, CDCl_3 , 330 K) δ 5.13 (br s, 1H), 4.72 (s, 2H), 3.38 (t, $J = 6.5$ Hz, 2H), 3.33 (dd, $J = 13.0$, 6.6 Hz, 2H), 1.83 (p, $J = 6.6$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3 , 298 K) δ 154.6, 95.5, 74.5, 48.9, 38.7, 28.9; HRMS (ESI, m/z): calcd for $\text{C}_6\text{H}_9\text{Cl}_3\text{N}_4\text{O}_2\text{Na}^+$, $[\text{M} + \text{Na}]^+$, 296.9683, found 296.9681.

2,2,2-Trichloroethyl (2-Azidopropyl)carbamate: IR $\nu_{\max}$ (neat)/ cm^{-1} : 3337 (br), 2936 (w), 2113 (s), 1717 (s), 1520 (s), 1453 (m), 1231 (s), 1153 (s), 1025 (m), 812 (s), 722 (s); ^1H NMR (400 MHz, CDCl_3) δ 5.26 (br s, 1H), 4.79–4.67 (m, 2H), 3.78–3.67 (m, 1H), 3.49–3.38 (m, 1H), 3.10 (ddd, $J = 13.9, 8.0, 5.6$ Hz, 1H), 1.30 (d, $J = 6.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 154.6, 95.4, 74.6, 57.4, 46.1, 16.7; HRMS (ESI, m/z): calcd for $\text{C}_6\text{H}_9\text{Cl}_3\text{N}_4\text{O}_2\text{Na}^+$, $[\text{M} + \text{Na}]^+$, 296.9683, found 296.9681.

Example 17. Preparation of 2,2,2-Trichloroethyl Allyl(methyl)carbamate




To a flame-dried flask (100 mL) equipped with a stir bar was added 2,2,2-trichloroethyl allylcarbamate (1.44 g, 6.2 mmol, 1.0 equiv). After flask was evacuated and backfilled with N_2 twice, anhydrous THF (40 mL) was added. After the flask was cooled to 0 °C, sodium hydride (298 mg, 7.44 mmol, 1.2 equiv, 60% in mineral oil) was added to the solution portion-wise. The reaction mixture was stirred for 30 min at 0 °C before a solution of methyl iodide (0.5 mL, 8.06 mmol, 1.3 equiv) in THF (5 mL) was added via a syringe. The reaction was warmed to 22 °C and kept stirring for 2 h until the starting material was fully consumed (monitored by TLC). EtOAc (15 mL) and saturated NH_4Cl solution (10 mL) were added to quench the reaction. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (20 mL $\times$ 3). The combined organic phase was washed with brine (20 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 5:1) to afford 2,2,2-trichloroethyl allyl(methyl)carbamate as yellow oil (917 mg, 60% yield).

IR $\nu_{\max}$ (neat)/ cm^{-1} : 2952 (w), 1714 (s), 1458 (m), 1402 (s), 1278 (m), 1232 (s), 1157 (s), 1114 (m), 1051 (m), 834 (m), 759 (m), 717 (s); ^1H NMR (400 MHz, CDCl_3 , 298 K): *rotamer* 1: δ 5.86–5.71 (m, 1H), 5.22–5.15 (m, 2H), 4.75 (s, 2H), 3.93 (d, $J = 5.2$ Hz, 2H), 2.96 (s, 3H); *rotamer* 2: δ 5.86–5.71 (m, 1H), 5.22–5.15 (m, 2H), 4.75 (s, 2H), 3.93 (d, $J = 5.2$ Hz, 2H), 2.94 (s, 3H); ^1H NMR (400 MHz, CDCl_3 , 330 K): δ 5.86–5.71 (m, 1H), 5.22–5.15 (m, 2H), 4.76 (s, 2H), 3.94 (d, $J = 5.6$ Hz, 2H), 2.96 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3 , 298 K): *rotamer* 1: δ 154.5, 132.5, 117.5,

95.7, 75.1, 51.8, 34.5; *rotamer* 2: δ 154.3, 132.5, 117.4, 95.6, 75.1, 51.4, 33.6; HRMS (ESI, m/z): calcd for $C_7H_{10}Cl_3NO_2Na^+$, $[M + Na]^+$, 267.9669, found 267.9665.

Note: in the ^1H NMR spectra of compound 2,2,2-trichloroethyl allyl(methyl)carbamate, two single peaks (2.96 and 2.94 ppm, s) belong to the methyl group were observed at 298 K and these two signals coalesced at 330 K. Therefore, we assigned one of the signals as the chemical shift from the rotamer of the other conformer.

Example 18. Synthesis of 2,2,2-Trichloroethyl (3-Azidopropyl)(methyl)carbamate




The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with several modifications: 0.3 equiv of 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one and 3.0 equiv of trimethylsilylazide were used; and the reaction was set up at 0 °C, slowly warmed to 22 °C over 0.5 hours, and was kept stirring for another 4 h at 22 °C. The crude product was purified by column chromatography (hexanes/EtOAc: from 100:1 to 5:1) to afford 2,2,2-trichloroethyl (3-azidopropyl)(methyl)carbamate as a colorless oil (211 mg, 73% yield).

IR ν_{max} (neat)/cm⁻¹: 2950 (w), 2094 (s), 1714 (s), 1404 (s), 1193 (s), 1142 (s), 1065 (m), 759 (m), 715 (s); ^1H NMR (400 MHz, CDCl₃, 298 K): *rotamer* 1: δ 4.74 (s, 2H), 3.45–3.32 (m, 4H) 3.00 (s, 3H), 1.90–1.65 (m, 2H); *rotamer* 2: δ 4.73 (s, 2H), 3.45–3.32 (m, 4H), 2.98 (s, 3H), 1.90–1.65 (m, 2H); ^1H NMR (400 MHz, CDCl₃, 330 K) δ 4.74 (s, 2H), 3.42 (t, J = 6.8 Hz, 2H), 3.34 (t, J = 6.6 Hz, 2H), 2.99 (s, 3H), 1.98–1.79 (m, 2H); ^{13}C NMR (100 MHz, CDCl₃, 298 K): *rotamer* 1: δ 154.5, 95.7, 75.1, 48.8, 46.9, 35.3, 27.3; *rotamer* 2: δ 154.3, 95.6, 75.1, 48.8, 46.5, 34.4, 26.8; HRMS (ESI, m/z): calcd for $C_7H_{11}Cl_3N_4O_2Na^+$, $[M + Na]^+$, 310.9840, found 310.9842.

Note: in the ^1H NMR spectra of 2,2,2-trichloroethyl (3-azidopropyl)(methyl)carbamate, two single peaks (3.00 and 2.98 ppm, s) belong to the methyl group were observed at 298 K. It was observed that these two signals coalesced at 330 K; therefore, we assigned one of the signals as the chemical shift from the rotamer of the other conformer.

5


Example 19. Preparation of *tert*-Butyl Allyl(2,2,2-trichloroethyl)dicarbamate



To a flame-dried flask (100 mL) equipped with a stir bar were added 2,2,2-trichloroethyl allylcarbamate (2.0 g, 8.6 mmol, 1.0 equiv) and Boc_2O (2.25 g, 10.3 mmol, 1.2 equiv). After this
 10 flask was evacuated and backfilled with N_2 twice, anhydrous CH_3CN (45 mL) was added, followed by the addition of DMAP (105 mg, 0.86 mmol, 0.1 equiv) in CH_3CN (2 mL) via a syringe. The reaction mixture was stirred for 1 h at 22 °C until the starting material was fully consumed (monitored by TLC), then the reaction mixture was evaporated *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 10:1) to afford *tert*-butyl
 15 allyl(2,2,2-trichloroethyl)dicarbamate as yellow oil (2.66 g, 93% yield).


IR ν_{max} (neat)/ cm^{-1} : 2982 (w), 1801 (m), 1759 (m), 1717 (s), 1427 (m), 1370 (s), 1344 (s), 1220 (s), 1120 (s), 1061 (m), 851 (m), 810 (m), 716 (s); ^1H NMR (400 MHz, CDCl_3) δ 5.98–5.76 (m, 1H), 5.29–5.10 (m, 2H), 4.81 (s, 2H), 4.30 (dt, J = 5.6, 1.3 Hz, 2H), 1.52 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 151.7, 151.3, 132.7, 117.3, 94.5, 83.7, 75.6, 48.8, 27.9; LRMS (ESI, m/z): calcd for $\text{C}_{11}\text{H}_{16}\text{Cl}_3\text{NO}_4\text{Na}^+$, $[\text{M} + \text{Na}^+]$, 354.00, found 354.07.
 20

25

Example 20. Synthesis of *tert*-Butyl 2,2,2-Trichloroethyl(3-azidopropyl)dicarbamate

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5 equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 5:1) to afford *tert*-butyl 2,2,2-trichloroethyl(3-azidopropyl)dicarbamate as a colorless oil (237 mg, 63% yield).

IR ν_{max} (neat)/cm⁻¹: 2981 (w), 2098 (s), 1800 (m), 1758 (m), 1726 (m), 1701 (s), 1451 (m), 1370 (s), 1256 (s), 1154 (s), 1114 (s), 851 (m), 811 (m), 762 (m), 716 (s); ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 2H), 3.81 (t, *J* = 7.2 Hz, 2H), 3.35 (t, *J* = 6.7 Hz, 2H), 1.93 (p, *J* = 6.8 Hz, 2H), 1.54 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 151.5, 94.5, 84.0, 75.6, 49.0, 44.4, 28.3, 27.9; HRMS (ESI, *m/z*): calcd for C₁₁H₁₇Cl₃N₄O₄Na⁺, [M + Na]⁺, 397.0208, found 397.0206.


Example 21. Synthesis of 2-(4-Azidobutyl)isoindoline-1,3-dione

2-(But-3-en-1-yl)isoindoline-1,3-dione was prepared using a known procedure (see Malkov, A.V. et al. *Chemistry - A European Journal* **2014**, 20, 4542).

The reaction was carried out on a 1.0 mmol scale and Procedure 2 of Example 2 was applied. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 5:1) to afford 2-(4-azidobutyl)isoindoline-1,3-dione as a colorless oil (211 mg, 86% yield).


IR ν_{max} (neat)/ cm^{-1} : 2944 (w), 2868 (w), 2092 (s), 1771 (m), 1703 (s), 1437 (m), 1395 (s), 1363 (m), 1042 (s), 865 (w), 794 (m), 717 (s); ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.72 (m, 2H), 7.70–7.64 (m, 2H), 3.67 (t, $J = 7.0$ Hz, 2H), 3.29 (t, $J = 6.8$ Hz, 2H), 1.81–1.67 (m, 2H), 1.66–1.53 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.2, 133.8, 131.9, 123.1, 50.7, 37.1, 26.1, 25.7; HRMS (ESI, m/z): calcd for $\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}_2\text{Na}^+$, $[\text{M} + \text{Na}]^+$, 267.0852, found 267.0850.

Example 22. Synthesis of 5-Azidopentanoic Acid




Pent-4-enoic acid is commercially available and was used directly without further purification.

The reaction was carried out on a 1.0 mmol scale. Procedure 1 of Example 1 was applied with some modifications: no external proton source (H_2O or trifluoroacetic acid) was added. The crude product was purified through column chromatography (hexanes/EtOAc: from 20:1 to 1:1) to afford 5-azidopentanoic acid as a colorless oil (119 mg, 83% yield) which is a known compound (see Mancuso, L. et al. *Chemistry - A European Journal* **2014**, 20, 17541).

Example 23. Synthesis of 4-Azidobutan-1-ol

But-3-en-1-ol is commercially available and was distilled before use.

The reaction was carried out on a 1.0 mmol scale. Procedure 1 of Example 1 was applied with several modifications: no external proton source (H_2O or trifluoroacetic acid) was added; and the reaction was quenched with aqueous HCl (1 M, 1.5 mL) and stirred for 15 minutes for protodesilylation of the alcohol functional group. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 3:1) to afford 4-azidobutan-1-ol as a colorless oil (92 mg, 80% yield) which is a known compound (see Khair, N. et al. *The Journal of Organic Chemistry* **2009**, 74, 6002).

Example 24. Synthesis of 4-(2-Azidoethyl)heptan-4-ol


4-Vinylheptan-4-ol was prepared using a known procedure (see Paquette, L.A. et al. *Tetrahedron Letters* **1976**, 17, 4033).

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification: 0.3 equiv of 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5

equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 3:1) to afford 4-(2-azidoethyl)heptan-4-ol as a colorless oil (135 mg, 73% yield).

IR ν_{max} (neat)/ cm^{-1} : 3446 (br), 2959 (s), 2934 (m), 2874 (m), 2091 (s), 1458 (m), 1256 (s), 1139 (s), 964 (m), 908 (m), 744 (m); ^1H NMR (400 MHz, CDCl_3) δ 3.40 (t, $J = 7.2$ Hz, 2H), 1.72 (t, $J = 7.2$ Hz, 2H), 1.49–1.38 (m, 4H), 1.38–1.20 (m, 4H), 0.92 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 73.6, 47.1, 41.6, 37.5, 16.8, 14.6; HRMS (ESI, m/z): calcd for $\text{C}_9\text{H}_{19}\text{N}_3\text{ONa}^+$, $[\text{M} + \text{Na}]^+$, 208.1420, found 208.1416.


10 Example 25. Synthesis of 2-Azido-3-methylbutyl Benzoate



3-Methylbut-2-en-1-yl benzoate was prepared using a known procedure (see Yasui, K. et al. *The Journal of Organic Chemistry* **1995**, 60, 1365).

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one and 2.5 equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford 2-azido-3-methylbutyl benzoate as a colorless oil (180 mg, 77% yield).


IR ν_{max} (neat)/ cm^{-1} : 2966 (m), 2096 (s), 1720 (s), 1452 (m), 1315 (m), 1267 (s), 1110 (s), 1070 (m), 1026 (m), 709 (s); ^1H NMR (400 MHz, CDCl_3) δ 8.09–8.05 (m, 2H), 7.57 (t, $J = 7.4$ Hz, 1H), 7.45 (t, $J = 7.7$ Hz, 2H), 4.56 (dd, $J = 11.6, 3.2$ Hz, 1H), 4.32 (dd, $J = 11.5, 8.5$ Hz, 1H), 3.58–3.50 (m, 1H), 1.92 (dq, $J = 13.2, 6.7$ Hz, 1H), 1.05 (d, $J = 6.8$ Hz, 3H), 1.03 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 133.1, 129.7, 129.5, 128.4, 67.0, 66.1, 29.8, 19.4, 18.2; HRMS (ESI, m/z): calcd for $\text{C}_{12}\text{H}_{15}\text{N}_3\text{O}_2\text{Na}^+$, $[\text{M} + \text{Na}]^+$, 256.1056, found 256.1061.

Example 26. Synthesis of 10-Azidodecanal

Dec-9-enal was prepared using a known procedure (see Lee, R.A. and Donald, D.S. *Tetrahedron Letters* **1997**, 38, 3857).

- 5 The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification. 0.2 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one, 3.0 equiv of trimethylsilylazide, and 0.6 equiv of trifluoroacetic acid were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford 10-azidodecanal as a colorless oil (140 mg, 71% yield).
- 10 IR ν_{max} (neat)/cm⁻¹: 2928 (s), 2856 (s), 2092 (s), 1706 (s), 1412 (m), 1251 (s), 911 (m), 724 (m); ¹H NMR (400 MHz, CDCl₃) δ 9.73 (t, J = 1.8 Hz, 1H), 3.23 (t, J = 6.9 Hz, 2H), 2.41 (dt, J = 7.3, 1.8 Hz, 2H), 1.62–1.53 (m, 4H), 1.43–1.25 (m, 10H); ¹³C NMR (100 MHz, CDCl₃) δ 202.7, 51.3, 43.8, 29.1 (2 carbon merged), 29.0, 28.9, 28.7, 26.6, 21.9; LRMS: m/z (EI) calcd for C₁₀H₁₉NO⁺, Exact Mass: 169.1 [M – N₂]⁺, 169.1, found 169.1.


15

Example 27: Synthesis of 4-Azido-1-phenylbutan-1-one

1-Penylbut-3-en-1-one was prepared using a known procedure (see Felpin, F.X. and Lebreton, J. *The Journal of Organic Chemistry* **2002**, 67, 9192).


The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification: 0.2 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5 equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford the desired product S44 as a colorless oil (144 mg, 76% yield) which is a known compound (see Ren, R. et al. *Angewandte Chemie International Edition* **2015**, 54, 12692).

10 Example 28. Synthesis of 1-Azido-6-bromohexane



6-Bromohex-1-ene is commercially available and was distilled before use.


The reaction was carried out on a 1.0 mmol scale, and Procedure 2 of Example 2 was applied. The crude product was purified through column chromatography (100% hexanes) to afford 1-azido-6-bromohexane as a colorless oil (186 mg, 90% yield) which is a known compound (see Coutrot, F. and Busseron, E. *Chemistry – A European Journal* **2009**, 15, 5186).

Example 29: Synthesis of 4-(Azidomethyl)-1,7-dichloroheptane

1,7-Dichloro-4-methyleneheptane was prepared using a known procedure (see Zhang, C. W. et al. *Journal of the American Chemical Society* **2013**, 135, 14082).

5 The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Examples 2 was applied with some modification: 0.3 equiv of 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one and 2.5 equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (100% hexanes) to afford 4-(azidomethyl)-1,7-dichloroheptane as a colorless oil (182 mg, 81% yield).


10 IR ν_{max} (neat)/ cm^{-1} : 2934 (m), 2868 (w), 2093 (s), 1452 (m), 1286 (s), 764 (m), 722 (s); ^1H NMR (400 MHz, CDCl_3) δ 3.53 (t, $J = 6.6$ Hz, 4H), 3.28 (d, $J = 5.7$ Hz, 2H), 1.87–1.72 (m, 4H), 1.69–1.58 (m, 1H), 1.54–1.41 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3) δ 54.8, 44.9, 37.2, 29.6, 28.9; LRMS: m/z (EI) calcd for $\text{C}_8\text{H}_{15}\text{Cl}_2\text{N}^+$, $[\text{M} - \text{N}_2]^+$, 195.1, found 195.1.

15 Example 30: Synthesis of Diethyl 3-(Azidomethyl)-4-methylcyclopentane-1,1-dicarboxylate

Diethyl 2,2-diallylmalonate was prepared using a known procedure (see Krafft, M. E. et al. *The Journal of Organic Chemistry* **2002**, 67, 1233).

The reaction was carried out on a 1.0 mmol scale, and Procedure 2 of Example 2 was applied. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford diethyl 3-(azidomethyl)-4-methylcyclopentane-1,1-dicarboxylate as a colorless oil (266 mg, 94% yield) which is a known compound (see Leggans, E. K. et al. *Organic Letters* **2012**, 14, 1428).

Example 31: Synthesis of (2*S*,5*S*)-5-(1-Azidopropan-2-yl)-2-methylcyclohexan-1-one




(-)-Dihydrocarvone was prepared using a known procedure (see Caboni, P. et al. *Journal of Agricultural and Food Chemistry* **2013**, 61, 9784).

The reaction was carried out on a 1.0 mmol scale. Procedure 2 of Example 2 was applied with some modification: 0.2 equiv of 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one and 2.5 equiv of trimethylsilylazide were used. The crude product was purified through column chromatography (hexanes/EtOAc: from 100:1 to 10:1) to afford (2*S*,5*S*)-5-(1-azidopropan-2-yl)-2-methylcyclohexan-1-one as a colorless oil (146 mg, 75% yield, dr: 1:1).

IR ν_{max} (neat)/cm⁻¹: 2966 (w), 2931 (m), 2872 (w), 2093 (s), 1709 (s), 1452 (m), 1271 (s), 1221 (m), 1145 (w), 960 (w), 861 (m), 710 (m); ¹H NMR (400 MHz, CDCl₃): (Diastereomer 1 and 2 overlap) δ 3.33–3.20 (m, 1H), 3.20–3.08 (m, 1H), 2.37–2.21 (m, 2H), 2.18–1.97 (m, 2H), 1.84–1.72 (m, 2H), 1.71–1.57 (m, 1H), 1.56–1.36 (m, 1H), 1.35–1.18 (m, 1H), 0.97 (d, *J* = 6.5 Hz, 3H), 0.92 (dd, *J* = 8.7, 4.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): Diastereomer 1: δ 212.3, 55.2, 45.8, 44.8, 42.1, 37.8, 34.6, 29.5, 14.2, 14.1; Diastereomer 2: δ 212.2, 55.2, 44.7, 43.9, 42.0, 37.8, 34.6, 27.3, 14.2, 14.1; LRMS: *m/z* (EI) calcd for C₁₀H₁₇NO⁺, [M – N₂]⁺, 167.1, found 167.1.

Example 32. Synthesis of (R)-((1S,2S,4S,5R)-5-(2-Azidoethyl)quinuclidin-2-yl)(6-methoxyquinolin-4-yl)methyl Acetate




(R)-((6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl acetate was prepared using a known procedure (see Monar, I. G. et al. *Journal of the American Chemical Society* **2016**, *138*, 5004).

To a flame-dried sealable 2-dram vial equipped with a stir bar were added (R)-((6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl acetate (183 mg, 0.5 mmol, 1.0 equiv) and 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1H)-one (66 mg, 0.25 mmol, 0.5 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.25 mL) was added, then the reaction was cooled to -10 °C, TFA (79 μL, 1.03 mmol, 2.05 equiv) was added. The reaction mixture was stirred for 20 min at -10 °C, then H₂O (5.4 μL, 0.3 mmol, 0.6 equiv) and TMSN₃ (197 μL, 1.5 mmol, 3 equiv) was added successively, follow by the addition of TFA (23 μL, 0.3 mmol), then the reaction was warmed to 22 °C and kept stirring for 4 h at the same temperature until the starting material was fully consumed (monitored by TLC). The reaction was cooled to 0 °C, quenched with EtOAc (2 mL) and saturated Na₂CO₃ solution (2 mL). The organic layer was separated from the aqueous layer, which was extracted with EtOAc (3 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was subsequently purified through a silica gel column (Et₂O/THF: from 100:1 to 3:1) to afford (R)-((1S,2S,4S,5R)-5-(2-azidoethyl)quinuclidin-2-yl)(6-methoxyquinolin-4-yl)methyl acetate as a colorless oil (139 mg, 68% yield).

IR ν_{max} (neat)/cm⁻¹: 2929 (m), 2866 (w), 2094 (s), 1742 (s), 1620 (s), 1508 (s), 1367 (m), 1225 (s), 1026 (s), 853 (m), 831 (m), 717 (m); ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, *J* = 4.5 Hz, 1H), 8.01

(d, $J = 9.2$ Hz, 1H), 7.42 (d, $J = 2.7$ Hz, 1H), 7.37 (dd, $J = 9.2, 2.7$ Hz, 1H), 7.34 (d, $J = 4.5$ Hz, 1H), 6.48 (d, $J = 7.2$ Hz, 1H), 3.95 (s, 3H), 3.43–3.18 (m, 3H), 3.15–3.02 (m, 2H), 2.64 (ddd, $J = 14.5, 11.4, 4.7$ Hz, 1H), 2.33 (dt, $J = 14.0, 3.1$ Hz, 1H), 2.13 (s, 3H), 1.89–1.47 (m, 8H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.0, 157.9, 147.4, 144.8, 143.5, 131.8, 127.0, 121.7, 118.8, 101.5, 73.7, 59.0, 57.8, 55.6, 49.7, 42.4, 33.8, 32.8, 28.2, 25.6, 24.0, 21.1; HRMS (ESI, m/z): calcd for $\text{C}_{22}\text{H}_{28}\text{N}_3\text{O}_3^+$, $[\text{M} + \text{H}^+]$, 410.2187, found 410.2182.

Example 33. Preparation of *tert*-Butyl 3-Allyl-4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate




tert-Butyl 4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate was prepared using a known procedure (see Yang, Y. et al. *Organic Letters* **2014**, *16*, 6216).

To a flame-dried flask (50 mL) equipped with a stir bar were added $^i\text{Pr}_2\text{NH}$ (1.28 mL, 9.1 mmol, 1.3 equiv) and anhydrous THF (20 mL). After the flask was cooled to -78°C , $n\text{-BuLi}$ (2.5 M in hexane, 3.64 mL, 9.1 mmol, 1.3 equiv) was added. After 30 min the mixture was transferred by a cannula to another flask (100 mL) containing a solution of *tert*-butyl 4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate (2.0 g, 7.0 mmol) in THF (30 mL) at -78°C . The resulting solution was stirred at -78°C for 1 h before a solution of allyl bromide (0.9 mL, 10.5 mmol, 1.5 equiv) in THF (10 mL) was added via a syringe. The reaction mixture was slowly warmed up to -20°C in 2 h and kept stirring for 5 h until the starting material was fully consumed (monitored by TLC). EtOAc (15 mL) and saturated NH_4Cl solution (10 mL) were added to quench the reaction. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (20 mL $\times$ 3). The combined organic phase was washed with brine (20 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 5:1) to afford *tert*-butyl 3-allyl-4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate as a white solid (1.66 g, 73% yield, m.p. $114\text{--}116^\circ\text{C}$).

IR ν_{max} (neat)/ cm^{-1} : 3078 (w), 2980 (m), 2934 (w), 1738 (s), 1664 (s), 1558 (m), 1483 (m), 1457 (s), 1369 (s), 1346 (s), 1318 (s), 1230 (m), 1143 (s), 1117 (s), 1077 (m), 900 (s), 831 (m), 767 (s), 732 (m); ^1H NMR (400 MHz, CDCl_3) δ 8.34–8.25 (m, 1H), 8.13–8.04 (m, 1H), 7.38–7.28 (m, 2H), 5.96–5.80 (m, 1H), 5.15–5.07 (m, 2H), 3.43 (dt, $J = 19.0, 5.0$ Hz, 1H), 3.21 (ddd, $J = 19.0, 9.5, 5.2$ Hz, 1H), 2.85–2.71 (m, 1H), 2.55 (ddt, $J = 10.5, 8.8, 4.4$ Hz, 1H), 2.37–2.19 (m, 2H), 2.05–1.90 (m, 1H), 1.71 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 196.6, 151.4, 149.8, 136.4, 136.0, 125.9, 124.8, 124.3, 121.5, 116.8 (2 carbon merged), 115.1, 85.3, 45.8, 33.6, 28.2, 28.0, 25.0; HRMS (ESI, m/z): calcd for $\text{C}_{20}\text{H}_{23}\text{NO}_3\text{Na}^+$, $[\text{M} + \text{Na}^+]$, 348.1570, found 348.1572.

10 **Example 34. Synthesis of *tert*-Butyl 3-(3-Azidopropyl)-4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate**




To a flame-dried sealable 2-dram vial equipped with a stir bar were added *tert*-butyl 3-allyl-4-oxo-1,2,3,4-tetrahydro-9H-carbazole-9-carboxylate (130 mg, 0.4 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1H)-one (42 mg, 0.16 mmol, 0.4 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.2 mL) and H_2O (4.3 μL , 0.24 mmol, 0.6 equiv) were added via syringes. After the vial was cooled to 0 °C, freshly distilled TMSN_3 (158 μL , 1.2 mmol, 3.0 equiv) was added to the reaction followed by the addition of TFA (18.4 μL , 0.24 mmol, 0.6 equiv). The mixture was warmed up to 22 °C and kept stirring for 4 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 °C, EtOAc (2 mL) and saturated NaHCO_3 solution (1.5 mL) were added to quench the reaction and to remove any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (3 mL $\times$ 3). The combined organic phase was washed

with brine (2 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/Et₂O: from 100:1 to 50:1) to afford *tert*-butyl 3-(3-azidopropyl)-4-oxo-1,2,3,4-tetrahydro-9*H*-carbazole-9-carboxylate as a colorless oil (106 mg, 72% yield).

- 5 IR ν_{max} (neat)/cm⁻¹: 2984 (m), 2932 (m), 2092 (s), 1743 (s), 1651 (s), 1561 (m), 1481 (m), 1457 (s), 1370 (s), 1351 (s), 1260 (m), 1146 (s), 1116 (s), 834 (w), 759 (s), 748 (s); ¹H NMR (400 MHz, CDCl₃) δ 8.30–8.24 (m, 1H), 8.12–8.04 (m, 1H), 7.36–7.30 (m, 2H), 3.44 (dt, *J* = 19.0, 5.2 Hz, 1H), 3.39–3.30 (m, 2H), 3.24 (ddd, *J* = 19.0, 9.0, 5.2 Hz, 1H), 2.56–2.43 (m, 1H), 2.36–2.28 (m, 1H), 2.07–1.93 (m, 2H), 1.82–1.73 (m, 2H), 1.71 (s, 9H), 1.63–1.54 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 197.0, 151.1, 149.8, 135.9, 125.8, 124.8, 124.3, 121.4, 116.7, 115.1, 85.4, 51.6, 45.7, 28.7, 28.2, 26.7, 26.5, 24.9; HRMS (ESI, *m/z*): calcd for C₂₀H₂₄N₄O₃Na⁺, [M + Na]⁺, 391.1741, found 391.1750.

15 **Example 36. Preparation of (3*S*,5*S*,10*S*,13*R*)-10,13-Dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl pent-4-enoate**




5 α -Cholestan-3 β -ol is commercially available and was used directly without further purification.

- 20 To a flame-dried flask (25 mL) equipped with a stir bar were added 5 α -Cholestan-3 β -ol (389 mg, 1.0 mmol, 1.0 equiv), DCC (268 mg, 1.3 mmol, 1.3 equiv), and DMAP (24.4 mg, 0.2 mmol, 0.2 equiv). After this flask was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (10 mL) and 4-pentenoic acid (120 mg, 1.2 mmol, 1.2 equiv) were added via syringes. After

stirring at 22 °C for 10 h, EtOAc (10 mL) and saturated NaHCO₃ solution (10 mL) were added to quench the reaction, the organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (10 mL × 3). The combined organic phase was washed with brine (15 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 10:1) to afford (3*S*,5*S*,10*S*,13*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl pent-4-enoate as a white solid (429 mg, 91% yield, m.p. 83–85 °C).

IR ν_{max} (neat)/cm⁻¹: 2928 (s), 2853 (s), 1733 (s), 1645 (w), 1469 (m), 1445 (m), 1382 (m), 1273 (m), 1177 (s), 998 (m), 912 (s), 734 (w); ¹H NMR (400 MHz, CDCl₃) δ 5.92–5.70 (m, 1H), 5.05 (d, *J* = 17.2 Hz, 1H), 4.99 (d, *J* = 11.2 Hz, 1H), 4.78–4.63 (m, 1H), 2.37–2.35 (m, 4H), 1.96 (dd, *J* = 9.4, 3.1 Hz, 1H), 1.86–1.75 (m, 2H), 1.75–1.68 (m, 1H), 1.64 (dt, *J* = 17.4, 5.5 Hz, 1H), 1.57–1.41 (m, 4H), 1.39–1.20 (m, 9H), 1.19–0.93 (m, 11H), 0.93–0.83 (m, 9H), 0.81 (s, 3H), 0.64 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.6, 136.8, 115.4, 73.7, 56.4, 56.3, 54.2, 44.7, 42.6, 40.0, 39.5, 36.8, 36.2, 35.8, 35.5 (2 carbon merged), 34.1, 33.9, 32.0, 29.0, 28.6, 28.2, 28.0, 27.5, 24.2, 23.8, 22.8, 22.6, 21.2, 18.7, 12.2, 12.1; HRMS (ESI, *m/z*): calcd for C₃₂H₅₄O₂Na⁺, [M + Na⁺], 493.40, found 493.43.


Example 37. Preparation of (3*S*,5*S*,10*S*,13*R*)-10,13-Dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 5-azidopentanoate



To a flame-dried sealable 2-dram vial equipped with a stir bar were added (3*S*,5*S*,10*S*,13*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl pent-4-enoate (235 mg, 0.5 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (53 mg, 0.2 mmol, 0.4 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.2 mL) and H₂O (5.4 μ L, 0.3 mmol, 0.6 equiv) were added via syringes. After the vial was cooled to 0 °C, freshly distilled TMSN₃ (164 μ L, 1.25 mmol, 2.5 equiv) was added to the reaction followed by the addition of TFA (7.7 μ L, 0.1 mmol, 0.2 equiv). The mixture was warmed up to 22 °C and kept stirring for 4 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 °C, EtOAc (2 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to remove any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/Et₂O: from 100:1 to 50:1) to afford (3*S*,5*S*,10*S*,13*R*)-10,13-dimethyl-17-((*R*)-6-methylheptan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl 5-azidopentanoate as a colorless oil (221 mg, 86% yield).

IR ν_{max} (neat)/cm⁻¹: 2930 (s), 2867 (s), 2096 (s), 1731 (s), 1508 (m), 1251 (m), 1177 (s), 1151 (s), 1006 (m), 929 (w), 737 (w); ¹H NMR (400 MHz, CDCl₃) δ 4.82–4.56 (m, 1H), 3.28 (t, *J* = 6.6 Hz, 2H), 2.30 (t, *J* = 7.1 Hz, 2H), 1.95 (dt, *J* = 12.3, 3.1 Hz, 1H), 1.86–1.75 (m, 2H), 1.74–1.42 (m, 12H), 1.40–1.20 (m, 10H), 1.19–0.94 (m, 11H), 0.89 (d, *J* = 6.5 Hz, 3H), 0.86 (d, *J* = 6.4 Hz, 3H), 0.85 (d, *J* = 6.8 Hz, 3H), 0.81 (s, 3H), 0.64 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.7, 73.8, 56.4, 56.2, 54.2, 51.0, 44.6, 42.6, 40.0, 39.5, 36.7, 36.1, 35.8, 35.4 (2 carbon merged), 34.0 (2 carbon merged), 32.0, 28.6, 28.2 (2 carbon merged), 28.0, 27.5, 24.2, 23.8, 22.8, 22.5, 22.2, 21.2, 18.6, 12.2, 12.0; HRMS (ESI, *m/z*): calcd for C₃₂H₅₅N₃O₂Na⁺, [M + Na]⁺, 536.4186, found 536.4182.

Example 38. Preparation of (2*R*,3*R*,4*S*,5*R*,6*S*)-2-((But-3-en-1-yloxy)methyl)-3,4,5,6-tetramethoxytetrahydro-2*H*-pyran




Methyl 2,3,4-Tri-*O*-methyl- α -*D*-glucopyranoside was prepared using a known procedure (see Boultradakis-Arapinis, M. et al. *Chemistry – A European Journal* **2013**, *19*, 6052).

To a flame-dried flask (10 mL) equipped with a stir bar were added methyl 2,3,4-tri-*O*-methyl- α -*D*-glucopyranoside (472 mg, 2.0 mmol, 1.0 equiv) and but-3-en-1-yl 4-methylbenzenesulfonate (905 mg, 4.0 mmol, 2.0 equiv). After the flask was evacuated and backfilled with N₂ twice, anhydrous THF (4 mL) was added. After the flask was cooled to 0 °C, NaH (120 mg, 3.0 mmol, 1.5 equiv, 60% in mineral oil) was added to the solution portion-wise. The reaction mixture was stirred for 20 min at 0 °C before warming to 50 °C and kept stirring for 24 h until the starting material was fully consumed (monitored by TLC). The reaction was cooled to 0 °C, Et₂O (5 mL) and saturated NH₄Cl solution (5 mL) were added to quench the reaction. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with Et₂O (5 mL × 3). The combined organic phase was washed with brine (5 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 50:1 to 3:1) to afford (2*R*,3*R*,4*S*,5*R*,6*S*)-2-((but-3-en-1-yloxy)methyl)-3,4,5,6-tetramethoxytetrahydro-2*H*-pyran as a colorless oil (348 mg, 60% yield).

IR ν_{max} (neat)/cm⁻¹: 2914 (m), 2835 (w), 1739 (w), 1642 (w), 1445 (w), 1376 (w), 1269 (m), 1189 (m), 1159 (s), 1099 (s), 1047 (s), 994 (s), 915 (m), 734 (s), 702 (s); ¹H NMR (400 MHz, CDCl₃) δ 5.76 (ddt, *J* = 17.1, 10.2, 6.8 Hz, 1H), 5.11–4.91 (m, 2H), 4.76 (d, *J* = 3.6 Hz, 1H), 3.58–3.54 (m, 2H), 3.55 (s, 3H), 3.53–3.48 (m, 2H), 3.47 (s, 3H), 3.44 (s, 3H), 3.43–3.37 (m, 2H), 3.33 (s, 3H), 3.20–3.09 (m, 2H), 2.35–2.26 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 135.0, 116.3, 97.3, 83.4, 81.6, 79.2, 70.8, 69.8, 69.1, 60.7, 60.3, 58.8, 54.9, 34.0; LRMS (ESI, *m/z*): calcd for C₁₄H₂₆O₆Na⁺, [*M* + Na⁺], 313.16, found 313.16.

Example 39. Synthesis of (2*R*,3*R*,4*S*,5*R*,6*S*)-2-((4-Azidobutoxy)methyl)-3,4,5,6-tetramethoxytetrahydro-2*H*-pyran




To a flame-dried sealable 2-dram vial equipped with a stir bar were added
 5 (2*R*,3*R*,4*S*,5*R*,6*S*)-2-((but-3-en-1-yloxy)methyl)-3,4,5,6-tetramethoxytetrahydro-2*H*-pyran (116 mg, 0.4 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (42 mg, 0.16 mmol, 0.4 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.2 mL) and H₂O (4.3 μ L, 0.24 mmol, 0.6 equiv) were added via syringes. After the vial was cooled to 0 °C, freshly distilled TMSN₃ (131 μ L, 1.0 mmol, 2.5 equiv) was added to the reaction
 10 followed by the addition of TFA (6.1 μ L, 0.08 mmol, 0.2 equiv). The mixture was warmed up to 22 °C and kept stirring for 4 h until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 °C, EtOAc (2 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to remove any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (3 mL $\times$ 3). The
 15 combined organic phase was washed with brine (2 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 100:1 to 3:1) to afford (2*R*,3*R*,4*S*,5*R*,6*S*)-2-((4-azidobutoxy)methyl)-3,4,5,6-tetramethoxytetrahydro-2*H*-pyran as a colorless oil (116 mg, 87% yield).

IR ν_{max} (neat)/cm⁻¹: 2935 (m), 2253 (w), 2099 (s), 1447 (w), 1376 (w), 1265 (m), 1159 (m), 1098
 20 (s), 1047 (s), 907 (s), 728 (s); ¹H NMR (400 MHz, CDCl₃) δ 4.81 (d, *J* = 3.6 Hz, 1H), 3.62 (s, 3H), 3.61–3.54 (m, 4H), 3.53 (s, 3H), 3.50 (s, 3H), 3.49–3.44 (m, 2H), 3.39 (s, 3H), 3.29 (t, *J* = 6.4 Hz, 2H), 3.23–3.14 (m, 2H), 1.74–1.60 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 97.5, 83.6, 81.7, 79.4,

70.9, 69.9, 69.3, 60.9, 60.5, 59.0, 55.1, 51.3, 26.8, 25.8; HRMS (ESI, m/z): calcd for $C_{14}H_{27}N_3O_6Na^+$, $[M + Na]^+$, 356.1792, found 356.1797.

Example 40. Large Scale Synthesis of *tert*-Butyl Dodecylcarbamate via Azide Intermediate



5


1-Dodecene is commercially available and was distilled before use.

The reaction was carried out on a 10 mmol scale, and Procedure 1 of Example 1 was applied. 1-Azidododecane was isolated as a colorless oil (1.9 g, 90% yield).

To a flask (100 mL) vial equipped with a stir bar were added 1-azidododecane (1.9 g, 9.0 mmol, 1.0 equiv) isolated from the last step, H_2O (1.62 mL, 90 mmol, 10 equiv) and THF (40 mL). After the flask was evacuated and backfilled twice with N_2 , a solution of PPh_3 (2.83 g, 10.8 mmol, 1.2 equiv) in THF (20 mL) was added drop-wise at $0\text{ }^\circ\text{C}$. The mixture was warmed up to $22\text{ }^\circ\text{C}$ and kept stirring for 8 h (monitored by TLC until the azide was fully consumed). Subsequently, Boc_2O (2.36 g, 10.8 mmol, 1.2 equiv) in THF (10 mL) was added to the above mixture drop-wise at $22\text{ }^\circ\text{C}$. The resulting mixture was stirred for additional 2 h until the amine intermediate was fully consumed (monitored by TLC). After concentration *in vacuo*, the residue was subsequently purified through column chromatography (hexanes/EtOAc: from 50:1 to 10:1) to afford *tert*-butyl dodecylcarbamate as a white solid (2.08 g, 81% yield, m.p. $37\text{--}39\text{ }^\circ\text{C}$).

IR ν_{max} (neat)/ cm^{-1} : 3380 (m), 2917 (s), 2851 (s), 1687 (s), 1514 (s), 1470 (m), 1364 (m), 1244 (s), 1044 (m), 975 (m), 868 (m), 719 (m); ^1H NMR (400 MHz, CDCl_3) δ 4.49 (br s, 1H), 3.14–3.05 (m, 2H), 1.47–1.40 (m, 11H), 1.27–1.24 (m, 18H), 0.88 (t, J = 6.8 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.0, 79.0, 40.6, 31.9, 30.1, 29.6 (four carbons merged), 29.3 (two carbons merged), 28.4, 26.8, 22.7, 14.1; HRMS (ESI, m/z): calcd for $\text{C}_{17}\text{H}_{35}\text{NO}_2\text{Na}^+$, $[\text{M} + \text{Na}]^+$, 308.2560, found 308.2564.

Example 41. Large Scale Synthesis of *tert*-Butyl (Bicyclo[2.2.1]heptan-2-yl)carbamate via Azide Intermediate



The reaction was carried out on a 12 mmol scale, and Procedure 1 of Example 1 was applied. 2-Azidobicyclo[2.2.1]heptane was isolated as a colorless oil (1.07 g, 65% yield).


15 To a 100 mL 2-neck round bottom flask equipped with a stir bar and a three-way adapter was added Pd/C (107 mg, 10 wt. %). After the flask was evacuated and backfilled twice with N_2 , a solution of 2-azidobicyclo[2.2.1]heptane (1.07 g, 7.8 mmol, 1.0 equiv) in THF (50 mL) was added. The mixture was degassed with brief evacuation and backfilled three times with H_2 , and then vigorously stirred under H_2 balloon at 22°C for 5 h (monitored by TLC until the azide **S11** was fully consumed). The solution was filtered through a Celite pad and washed with MeOH (20 mL). The combined filtrates were concentrated to afford the crude amine, which was then

20

dissolved in 40 mL THF, Boc₂O (2.04 g, 9.36 mmol, 1.2 equiv) in THF (10 mL) was added to the above mixture drop-wise at 0 °C. The resulting mixture was warmed up to room temperature and kept stirring for additional 2 h until the amine intermediate was fully consumed (monitored by TLC). After concentration *in vacuo*, the residue was subsequently purified through column chromatography (hexanes/EtOAc: from 20:1 to 10:1) to afford *tert*-butyl (bicyclo[2.2.1]heptan-2-yl)carbamate as a white solid (1.37 g, 83% yield, m.p. 107–109 °C).

IR ν_{max} (neat)/cm⁻¹: 3357 (m), 2955 (m), 2874 (m), 1683 (s), 1521 (s), 1366 (m), 1308 (m), 1250 (m), 1171 (s), 1068 (m), 863 (m), 721 (m); ¹H NMR (400 MHz, CDCl₃, 330K) δ 4.31 (br s, 1H), 3.44 (s, 1H), 2.24–2.18 (m, 2H), 1.76–1.70 (m, 1H), 1.61–1.41 (m, 11H), 1.35–1.28 (m, 1H), 1.20–1.08 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 155.2, 79.0, 53.8, 42.5, 40.4, 35.6, 35.3, 28.4, 28.1, 26.4; HRMS (ESI, m/z): calcd for C₁₂H₂₁NO₂Na⁺, [M + Na]⁺, 234.1465, found 234.1469.

Example 42. Olefin Isomerization Study



(Z)-Hex-3-en-1-ol is commercially available and was distilled before use.

To a flame-dried sealable 2-dram vial equipped with a stir bar were added **A** (200 mg, 2.0 mmol) and 1-hydroxy-1λ³-benzo[*d*][1,2]iodaoxol-3(1*H*)-one (106 mg, 0.4 mmol). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.67 mL) was added, followed by the addition of TMSN₃ (526 μL, 4.0 mmol). The reaction mixture was stirred at 22 °C and quenched with aqueous H₂SO₄ (1 M, 1.5 mL) at 15, 40, 120, or 180 minutes. The organic layer was separated from the aqueous layer, which was extracted with Et₂O (3 mL × 3). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The reaction mixture was purified through column chromatography (hexanes/EtOAc: from 50:1 to 5:1) to afford **C** as

colorless oil (62 mg, 43% yield) and **D** as colorless oil (47 mg, 33% yield) or to recover **A** as well as **B**.

4-Azidohexan-1-ol (C): IR ν_{max} (neat)/ cm^{-1} : 3338 (br), 2937 (m), 2877 (m), 2092 (s), 1457 (m), 1340 (m), 1272 (s), 1250 (s), 1050 (s), 926 (m), 775 (w); ^1H NMR (400 MHz, CDCl_3) δ 3.65 (t, J = 5.9 Hz, 2H), 3.32–3.09 (m, 1H), 1.73–1.45 (m, 6H), 0.98 (t, J = 7.4 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 64.3, 62.4, 30.3, 29.2, 27.4, 10.4; HRMS (ESI, m/z): calcd for $\text{C}_6\text{H}_{13}\text{N}_3\text{ONa}^+$, [$\text{M} + \text{Na}^+$], 166.0951, found 166.0953.


3-Azidohexan-1-ol (D): IR ν_{max} (neat)/ cm^{-1} : 3343 (br), 2960 (m), 2936 (m), 2876 (m), 2095 (s), 1463 (m), 1339 (m), 1254 (s), 1121 (w), 1047 (s), 905 (m), 744 (m); ^1H NMR (400 MHz, CDCl_3) δ 3.80–3.72 (m, 2H), 3.51 (tt, J = 9.2, 4.6 Hz, 1H), 1.84–1.73 (m, 1H), 1.71–1.63 (m, 1H), 1.61–1.33 (m, 4H), 0.95 (t, J = 7.1 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 59.9, 59.8, 36.8, 36.7, 19.3, 13.8; HRMS (ESI, m/z): calcd for $\text{C}_6\text{H}_{13}\text{N}_3\text{ONa}^+$, [$\text{M} + \text{Na}^+$], 166.0951, found 166.0953.

The yields of **B**, **C**, and **D** in addition to recovered **A** at the various time points are provided in Table 1 below.

Table 1. Yields Isolated at Various Time Points for Hydroazidation of (Z)-Hex-3-en-1-ol

Time	A recovered (%)	B yield (%)	C yield (%)	D yield (%)
15 min	25	51	11	10
40 min	6	32	31	25
120 min	2	17	43	33
180 min	2	17	43	33

Example 43. Trapping of Radical Intermediate by TEMPO During Hydroazidation of 1-Dodecene




1-Dodecene is commercially available and was distilled before use.

5 To a flame-dried sealable 2-dram vial equipped with a stir bar were added 1-dodecene (222 μL, 1.0 mmol, 1.0 equiv), TEMPO (156 mg, 1.0 mmol, 1.0 equiv) and 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one (53 mg, 0.2 mmol, 0.2 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.33 mL) and H₂O (18 μL, 1.0 mmol, 1.0 equiv) were added via syringes. Freshly distilled TMSN₃ (263 μL, 2.0 mmol, 2.0 equiv) was added to the
 10 reaction and the mixture was stirred for 6 h at 22 °C until the olefin was not further consumed (monitored by TLC). The reaction was cooled to 0 °C. Et₂O (2 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to remove any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with Et₂O (3 mL × 3). The combined organic phase was washed with brine (2 mL) and dried over
 15 Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/Et₂O: from 100:0 to 10:1) to afford 1-((1-azidododecan-2-yl)oxy)-2,2,6,6-tetramethylpiperidine as colorless oil (92 mg, 25% yield).

IR ν_{max} (neat)/cm⁻¹: 2924 (s), 2854 (m), 2098 (s), 1466 (m), 1376 (m), 1361 (m), 1259 (m), 1182 (m), 1045 (m), 890 (m), 788 (m); ¹H NMR (400 MHz, CDCl₃) δ 3.94–3.85 (m, 1H), 3.53 (dd, *J* = 12.4, 4.4 Hz, 1H), 3.34 (dd, *J* = 12.4, 5.5 Hz, 1H), 1.84–1.70 (m, 1H), 1.52–1.41 (m, 5H), 1.35–1.20 (m, 18H), 1.14–1.12 (m, 12H), 0.88 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 80.90, 60.1, 59.8, 53.3, 40.3, 34.3, 34.1, 31.9, 31.3, 29.9, 29.6 (2 carbon merged), 29.3, 25.8, 22.7, 20.4, 17.2, 14.1; HRMS (ESI, *m/z*): calcd for C₂₁H₄₃N₄O⁺, [*M* + H⁺], 367.3431, found 367.3433.
 20

Example 44. Trapping of Radical Intermediate by TEMPO During Hydroazidation of Styrene




Styrene is commercially available and was distilled before use.

5 To a flame-dried sealable 2-dram vial equipped with a stir bar were added TEMPO (156 mg, 1.0 mmol, 1.0 equiv) and 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one (53 mg, 0.2 mmol, 0.2 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.33 mL), styrene (105 mg, 1.0 mmol, 1.0 equiv), and H₂O (18 μL, 1.0 mmol, 1.0 equiv) were added successively via syringes. Freshly distilled TMSN₃ (263 μL, 2.0 mmol, 2.0 equiv) was added to
 10 the reaction and the mixture was stirred for 6 h at 22 °C until the olefin was not further consumed (monitored by TLC). The reaction was cooled to 0 °C, Et₂O (2 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to remove any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with Et₂O (3 mL × 3). The combined organic phase was washed with brine (2 mL) and dried over
 15 Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/Et₂O: from 100:0 to 10:1) to afford 1-(2-azido-1-phenylethoxy)-2,2,6,6-tetramethylpiperidine as colorless oil (115 mg, 38% yield) which is a known compound.

20


25

Example 45. Deuteroazidation of 2-Norbornene

2-Norbornene is commercially available and was used directly without further purification.


To a flame-dried sealable 2-dram vial equipped with a stir bar were added 2-Norbornene (94 mg, 1.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (27 mg, 0.1 mmol, 0.1 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.2 mL) and D_2O (27 μL , 1.5 mmol, 1.5 equiv) were added via syringes. Freshly distilled $TMSN_3$ (328 μL , 2.5 mmol, 2.5 equiv) was added to the reaction and the mixture was stirred for 4 h at 22 $^\circ C$ until the olefin was fully consumed (monitored by TLC). The reaction was cooled to 0 $^\circ C$, Hexanes (2 mL) and saturated $NaHCO_3$ solution (1.5 mL) were added to quench the reaction and to neutralize the residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na_2SO_4 . After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford 2-Azidobicyclo[2.2.1]heptane-3-d as a colorless oil (90 mg, 65% yield).

IR ν_{max} (neat)/ cm^{-1} : 2957 (s), 2874 (m), 2085 (s), 1454 (m), 1339 (m), 1247 (s), 971 (s), 767 (w), 742 (w); ^1H NMR (400 MHz, $CDCl_3$) δ 3.49–3.46 (m, 1H), 2.31–2.29 (m, 2H), 1.66–1.53 (m, 2H), 1.52–1.42 (m, 2H), 1.20–1.18 (m, 1H), 1.16–1.04 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 64.3, 41.8, 37.9 (q, $J = 20$ Hz), 35.6, 35.3, 28.3, 25.9; LRMS: m/z (EI) calcd for $C_7H_{10}DN^+$, $[M - N_2]^+$, 110.1, found 110.1.

Example 46. Synthesis of an Oligomeric Azide Product from Ethyl Acrylate

Ethyl acrylate is commercially available and was distilled before use.


To a flame-dried sealable 2-dram vial equipped with a stir bar was added 1-hydroxy-1λ³-benzo[d][1,2]iodaoxol-3(1*H*)-one (12 mg, 0.046 mmol, 0.01 equiv). After this vial was evacuated and backfilled with N₂ twice, ethyl acrylate (0.5 mL, 4.59 mmol, 1.0 equiv) and H₂O (4.1 μL, 0.23 mmol, 0.05 equiv) were added via syringes. Freshly distilled trimethylsilylazide (60 μL, 0.46 mmol, 0.1 equiv) was added to the reaction, and the mixture was stirred at 22 °C. During this period, polymer was generated gradually. After 0.5 h, Et₂O (3 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to neutralize any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with Et₂O (3 mL × 3). The combined organic phase was washed with brine (2 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the product was obtained as a white solid.

Example 47. Synthesis of a Deuterated Oligomeric Azide Product from Ethyl Acrylate

Ethyl acrylate is commercially available and was distilled before use.

To a flame-dried sealable 2-dram vial equipped with a stir bar was added 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (12 mg, 0.046 mmol, 0.01 equiv). After this vial was evacuated and backfilled with N₂ twice, Ethyl acrylate (0.5 mL, 4.59 mmol, 1.0 equiv) and D₂O (4.1 μ L, 0.23 mmol, 0.05 equiv) were added via syringes. Freshly distilled trimethylsilylazide (60 μ L, 0.46 mmol, 0.1 equiv) was added to the reaction and the mixture was stirred at 22 °C. During this period, polymer was generated gradually. After 1 h, Et₂O (3 mL) and saturated NaHCO₃ solution (1.5 mL) were added to quench the reaction and to neutralize any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with Et₂O (3 mL $\times$ 3). The combined organic phase was washed with brine (2 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the product was obtained as a white solid.

Example 48. Deuteroazidation of 1-Dodecene with Deuterium Oxide as the Hydrogen Bond Donor




15

To a flame-dried sealable 3-dram vial equipped with a stir bar were added 1-dodecene (444 μ L, 2.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[*d*][1,2]iodaoxol-3(1*H*)-one (27 mg, 0.1 mmol, 0.05 equiv). After this vial was evacuated and backfilled with N₂ twice, anhydrous CH₂Cl₂ (0.4 mL) and D₂O (51 μ L, 2.8 mmol, 1.4 equiv) were added via syringes. Freshly distilled trimethylsilylazide (656 μ L, 5.0 mmol, 2.5 equiv) was added to the reaction and the mixture was stirred for 4 h at 22 °C. The reaction was cooled to 0 °C, Hexanes (4 mL) and saturated NaHCO₃ solution (2 mL) were added to quench the reaction and to neutralize any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted

with hexanes (4 mL $\times$ 3). The combined organic phase was washed with brine (4 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford the inseparable regioisomers 1-azidododecane-2-*d* and 2-azidododecane-1-*d* as a colorless oil (89 mg, 21% yield, 6.7:1 ratio, 80% deuterium incorporation).

In order to confirm the structures of compound 1-azidododecane-2-*d* and 2-azidododecane-1-*d*, we further reduced the azido group with Ph₃P and subsequently protected with an acetyl group to afford *N*-(dodecyl-2-*d*)acetamide and *N*-(dodecan-2-yl-1-*d*)acetamide.




To a flame-dried sealable 3-dram vial equipped with a stir bar were added the inseparable products 1-azidododecane-2-*d* and 2-azidododecane-1-*d* (89 mg, 0.42 mmol, 1.0 equiv. After this vial was evacuated and backfilled with N₂ twice, THF (3 mL) and H₂O (38 μ L, 2.1 mmol, 5.0 equiv) were added via syringes. Subsequently, triphenylphosphine (132 mg, 0.5 mmol, 1.2 equiv) in THF (1.2 mL) was added drop-wise to the reaction at 0 °C. The reaction mixture was warmed up to 50 °C and stirred for 8 h (monitored by IR until the absorption of azido groups disappeared). The reaction mixture was cooled to room temperature, Et₃N (117 μ L, 0.84 mmol, 2.0 equiv), Ac₂O (79 μ L, 0.84 mmol, 2.0 equiv) and a solution of DMAP (10 mg, 0.08 mmol, 0.2 equiv) in THF (0.5 mL) were added to the above mixture at 0 °C. The reaction mixture was warmed up to room temperature and kept stirring for additional 2 h until the intermediate was consumed (monitored by TLC). Saturated NaHCO₃ solution (2 mL) and ethyl acetate (3 mL) were added to quench the reaction. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with EtOAc (3 mL $\times$ 3). The combined organic phase was washed with brine (4 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (hexanes/EtOAc: from 20:1 to 1:1) to afford *N*-(dodecyl-2-*d*)acetamide as a white solid (71 mg, 85% yield) along with *N*-(dodecan-2-yl-1-*d*)acetamide as a white solid (11 mg, 85% yield).

N-(dodecyl-2-*d*)acetamide: ^1H NMR (400 MHz, CDCl_3) δ 8.14 (brs, 1H), 3.27–3.25 (m, 2H), 2.19 (s, 3H), 1.57–1.51 (m, 1H), 1.35–1.21 (m, 18H), 0.86 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.3, 40.6 (d, $J = 6.5$ Hz), 31.9, 29.6 (two carbons overlapped each other), 29.5 (two carbons overlapped each other), 29.3, 29.2 (d, $J = 3.1$ Hz), 28.6 (q, $J = 20$ Hz), 26.8 (d, $J = 9.9$ Hz), 22.6, 21.7, 14.1; HRMS (ESI, m/z): calcd for $\text{C}_{14}\text{H}_{28}\text{DNONa}^+$, $[\text{M} + \text{Na}^+]$, 251.2204, found 251.2201.

N-(dodecan-2-yl-1-*d*)acetamide: ^1H NMR (400 MHz, CDCl_3) δ 5.24 (d, $J = 6.8$ Hz, 1H), 4.05–3.84 (m, 1H), 1.95 (s, 3H), 1.42–1.21 (m, 18H), 1.12–1.08 (m, 2H), 0.87 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 45.3 (d, $J = 5.1$), 37.0 (d, $J = 2.6$ Hz), 31.9, 29.6 (three carbon overlapped each other), 29.5, 29.3, 26.0, 23.6, 22.7, 20.7 (q, $J = 10.0$ Hz), 14.1; HRMS (ESI, m/z): calcd for $\text{C}_{14}\text{H}_{28}\text{DNONa}^+$, $[\text{M} + \text{Na}^+]$, 251.2204, found 251.2201.

Example 49. Deuteroazidation of 1-Dodecene with Deuterium Oxide and Trifluoroacetic Acid-*d* as the Hydrogen Bond Donor



To a flame-dried sealable 3-dram vial equipped with a stir bar were added 1-Dodecene (444 μL , 2.0 mmol, 1.0 equiv) and 1-hydroxy-1 λ^3 -benzo[d][1,2]iodaoxol-3(1*H*)-one (53 mg, 0.2 mmol, 0.1 equiv). After this vial was evacuated and backfilled with N_2 twice, anhydrous CH_2Cl_2 (0.4 mL) and D_2O (25 μL , 1.4 mmol, 0.7 equiv) were added via syringes. Freshly distilled trimethylsilylazide (656 μL , 5.0 mmol, 2.5 equiv) was added to the reaction followed by $\text{CF}_3\text{CO}_2\text{D}$ (108 μL , 1.4 mmol, 0.7 equiv), and the mixture was stirred for 4 h at 22 $^\circ\text{C}$. The reaction was cooled to 0 $^\circ\text{C}$, hexanes (4 mL) and saturated NaHCO_3 solution (2 mL) were added to quench the

reaction and to neutralize any residual hydrazoic acid. The organic phase was separated from the aqueous phase, and the aqueous phase was extracted with hexanes (4 mL $\times$ 3). The combined organic phase was washed with brine (4 mL) and dried over Na₂SO₄. After concentration *in vacuo*, the residue was purified through column chromatography (100% hexanes) to afford the inseparable regioisomers 1-azidododecane-2-*d* and 2-azidododecane-1-*d* as a colorless oil as colorless oil (183 mg, 43% yield, 6.5:1 ratio, 74% deuterium incorporation).


All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for the purposed of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teaching of this invention that certain changes and modifications may be made thereto without departing from the spirit and scope of the invention as defined in the appended claims.

CLAIMS

I Claim:

1. A process for preparing an organic azide of Formula III comprising mixing an olefin of Formula I, a silylazide of Formula II, a hydrogen bond donor, and an organic promoter:



wherein:

R^1 and R^2 are independently selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein each of R^1 and R^2 that is not hydrogen is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N}(\text{R}^7)(\text{R}^7)$, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, $-\text{O}(\text{C}=\text{O})\text{R}^7$, $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{R}^7$, $-\text{O}(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, and $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{OR}^7$;


wherein at least one of R^1 and R^2 is not hydrogen;

R^3 is selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein R^3 other than hydrogen is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N}(\text{R}^7)(\text{R}^7)$, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, $-\text{O}(\text{C}=\text{O})\text{R}^7$, $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{R}^7$, $-\text{O}(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, and $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{OR}^7$; or

R^1 and R^2 or R^2 and R^3 are taken together with the carbons to which they are attached to form a cycloalkyl ring or an heterocycloalkyl ring, wherein each cycloalkyl or heterocycloalkyl ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N}(\text{R}^7)(\text{R}^7)$, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, $-\text{O}(\text{C}=\text{O})\text{R}^7$, $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{R}^7$, $-\text{O}(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, and $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{OR}^7$;

R^4 is independently selected at each occurrence from alkyl and cycloalkyl;

the organic promoter is selected from:



R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

m is 1, 2, 3, or 4;

Z is I;

R^6 and $R^{6'}$ are independently selected from $-O(C=O)R^7$, $-O(SO_2)(R^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or


R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group;

R^9 is aryl or heteroaryl, wherein R^9 is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; and

the hydrogen bond donor is water and optionally a second hydrogen bond donor.

2. A process for preparing an oligomer or polymer of Formula V comprising mixing an olefin of Formula IV, a silyl azide of Formula II, an organic promoter, and a hydrogen bond donor:



wherein:

R^{10} , R^{11} , and R^{12} are independently selected from hydrogen, halogen, cyano, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each of R^{10} , R^{11} , and R^{12} other than hydrogen, halogen, or cyano may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

or R^{11} and R^{12} may be brought together with the carbons to which they are attached to form a cycloalkyl ring or a heterocycloalkyl ring, each of which cycloalkyl or heterocycloalkyl ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

R^{13} is selected from cyano, nitro, $-(C=O)R^{7a}$, $-(C=O)OR^{7a}$, and $-(C=O)N(R^{7a})(R^{7b})$;

R^{7a} and R^{7b} are independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^{7a} and R^{7b}


other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

R^{7a} and R^{7b} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

R^{10} and R^{7a} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^4 is independently selected at each occurrence from alkyl and cycloalkyl;

the organic promoter is selected from:



R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

R^6 and $R^{6'}$ are independently selected from $-O(C=O)R^7$, $-O(SO_2)(R^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group;

R^9 is aryl or heteroaryl, wherein R^9 is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

Z is I;


m is 1, 2, 3, or 4;

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25;

and

the hydrogen bond donor is water and optionally a second hydrogen bond donor.

3. A process for preparing an organic azide of Formula VI comprising mixing an olefin of Formula I, a silylazide of Formula II, a deuterium bond donor, and an organic promoter:



wherein:

R¹ and R² are independently selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein each of R¹ and R² that is not hydrogen is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷;


wherein at least one of R¹ and R² is not hydrogen;

R³ is selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, and heterocycloalkyl, wherein R³ other than hydrogen is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷; or

R¹ and R² or R² and R³ are taken together with the carbons to which they are attached to form a cycloalkyl ring or an heterocycloalkyl ring, wherein each cycloalkyl or heterocycloalkyl ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷;

R⁴ is independently selected at each occurrence from alkyl and cycloalkyl;

the organic promoter is selected from:



R⁵ is independently selected from hydrogen, halo, cyano, azido, nitro, R⁷, -OR⁷, -N(R⁷)(R⁷), -(C=O)R⁷, -(C=O)OR⁷, -(C=O)N(R⁷)(R⁷), -O(C=O)R⁷, -N(R⁷)(C=O)R⁷, -O(C=O)N(R⁷)(R⁷), and -N(R⁷)(C=O)OR⁷;

Z is I;

m is 1, 2, 3, or 4;

R^6 and $R^{6'}$ are independently selected from $-O(C=O)R^7$, $-O(SO_2)(R^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or


R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group;

R^9 is aryl or heteroaryl, wherein R^9 is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; and

the deuterium bond donor is deuterium oxide and optionally a second deuterium bond donor.

4. A process for preparing an oligomer or polymer of Formula XI comprising mixing an olefin of Formula IV, a silyl azide of Formula II, an organic promoter, and a deuterium bond donor:



wherein:

R^{10} , R^{11} , and R^{12} are independently selected from hydrogen, halogen, cyano, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein each of R^{10} , R^{11} , and R^{12} other than hydrogen, halogen, or cyano may be optionally substituted with one or more substituents that do not adversely affect the desired reaction, for example a substituent selected from oxo, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N}(\text{R}^7)(\text{R}^7)$, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, $-\text{O}(\text{C}=\text{O})\text{R}^7$, $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{R}^7$, $-\text{O}(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, and $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{OR}^7$; or

or R^{11} and R^{12} may be brought together with the carbons to which they are attached to form a cycloalkyl ring or a heterocycloalkyl ring, each of which cycloalkyl or heterocycloalkyl ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N}(\text{R}^7)(\text{R}^7)$, $-(\text{C}=\text{O})\text{R}^7$, $-(\text{C}=\text{O})\text{OR}^7$, $-(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, $-\text{O}(\text{C}=\text{O})\text{R}^7$, $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{R}^7$, $-\text{O}(\text{C}=\text{O})\text{N}(\text{R}^7)(\text{R}^7)$, and $-\text{N}(\text{R}^7)(\text{C}=\text{O})\text{OR}^7$;

R^{13} is selected from cyano, nitro, $-(\text{C}=\text{O})\text{R}^{7a}$, $-(\text{C}=\text{O})\text{OR}^{7a}$, and $-(\text{C}=\text{O})\text{N}(\text{R}^{7a})(\text{R}^{7b})$;

R^{7a} and R^{7b} are independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^{7a} and R^{7b} other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or


R^{7a} and R^{7b} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more

substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

R^{10} and R^{7a} may be brought together with the atoms to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^4 is independently selected at each occurrence from alkyl and cycloalkyl;

the organic promoter is selected from:



R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-\text{OR}^7$, $-\text{N(R}^7\text{)(R}^7\text{)}$, $-(\text{C=O})\text{R}^7$, $-(\text{C=O})\text{OR}^7$, $-(\text{C=O})\text{N(R}^7\text{)(R}^7\text{)}$, $-\text{O}(\text{C=O})\text{R}^7$, $-\text{N(R}^7\text{)(C=O)R}^7$, $-\text{O}(\text{C=O})\text{N(R}^7\text{)(R}^7\text{)}$, and $-\text{N(R}^7\text{)(C=O)OR}^7$;

R^6 and $R^{6'}$ are independently selected from $-\text{O}(\text{C=O})\text{R}^7$, $-\text{O}(\text{SO}_2)(\text{R}^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group;

R^9 is aryl or heteroaryl, wherein R^9 is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

Z is I;


m is 1, 2, 3, or 4;

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25;


and

the deuterium bond donor is deuterium oxide and optionally a second deuterium bond donor.


5. The process of claim 1 or 3, wherein Formula I is selected from




6. The process of claim 1 or 3, wherein Formula I is selected from




7. The process of claim 1 or 3, wherein Formula I is selected from




8. The process of claim 6, wherein Formula I is selected from




9. The process of claim 6, wherein Formula I is selected from




10. The process of claim 6, wherein Formula I is selected from









11. The process of claim 6, wherein Formula I is selected from




12. The process of claim 6, wherein Formula I is selected from




13. The process of claim 2 or 4, wherein Formula IV is a compound of Formula IVa, IVb, IVc, IVd, IVe, or IVf:



14. The process of claim 2 or 4, wherein Formula IV is selected from



15. The process of claim 2 or 4, wherein Formula IV is selected from




16. The process of any one of claims 1-2 and 5-15, wherein the hydrogen bond donor is water.
17. The process of any one of claims 1-2 and 5-15, wherein the hydrogen bond donor is water and a second hydrogen bond donor selected from formic acid, an alkylcarboxylic acid, a (cycloalkyl)carboxylic acid, a (heteroalkyl)carboxylic acid, a (heterocycloalkyl)carboxylic acid, an arylcarboxylic acid, an (heteroaryl)carboxylic acid, sulfuric acid, an alkylsulfonic acid, a (cycloalkyl)sulfonic acid, a (heteroalkyl)sulfonic acid, a (heterocycloalkyl)sulfonic acid, an arylsulfonic acid, and a (heteroaryl)sulfonic acid.
18. The process of claim 17, wherein the hydrogen bond donor is water and trifluoroacetic acid.
19. The process of any one of claims 3-15, wherein the deuterium bond donor is deuterium oxide.
20. The process of any one of claims 3-15, wherein the deuterium bond donor is deuterium oxide and a second deuterium bond donor selected from trifluoroacetic acid-d, acetic acid-d₄, trifluoromethanesulfonic acid-d, methanesulfonic acid-d₄, and formic acid-d₂.


21. The process of any one of claims 3, 5-12, and 19-20 wherein the deuterium is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated into Formula IV.

22. The process of any one of claims 4, 13-15, and 19-20 wherein the deuterium is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.9%, 99.99%, or 99.999% incorporated into Formula VIII.


23. The process of any one of claim 1-22, wherein the organic promoter is




24. The process of claim 23, wherein the organic promoter is selected from




25. The process of claim 23, wherein the organic promoter is selected from



26. The process of any one of claim 1-22, wherein the organic promoter is



27. The process of claim 26, wherein the organic promoter is selected from



wherein o is 1, 2, 3, 4, or 5.



28. The process of claim 24 or 27, wherein R^7 is trifluoromethyl or trichloromethyl.

29. The process of any one of claims 1-28, wherein R^4 is alkyl.

30. The process of any one of claims 1-28, wherein Formula II is trimethylsilylazide.

31. The process of any one of claims 1-28, wherein Formula II is triethylsilylazide.

32. A compound of Formula VII or Formula VIII



wherein

R^4 is independently selected at each occurrence from alkyl and cycloalkyl;

R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^{14} and $R^{14'}$ are selected from $-O(C=O)R^7$ and $-O(SO_2)(R^7)$;

Z is I; and

m is 1, 2, 3, or 4.

33. The compound of claim 32, wherein R^5 is hydrogen.


34. The compound of claim 32 or 33, wherein R^4 is alkyl.

35. The compound of claim 34, wherein R^4 is independently selected from methyl, ethyl, and tert-butyl.


36. The compound of any one of claims 32-35, wherein R^{14} and $R^{14'}$ are selected from $-O(C=O)R^7$.

37. The compound of any one of claims 32-35, wherein R^{14} and $R^{14'}$ are selected from $-O(SO_2)(R^7)$.

38. The compound of claim 36 or 37, wherein R^7 is selected from alkyl, heteroalkyl, and aryl.
39. The compound of claim 38, wherein R^7 is trifluoromethyl or trichloromethyl.
40. The compound of claim 38, wherein R^7 is methyl.
41. The compound of claim 38, wherein R^7 is phenyl.
42. The process of claim 1, further comprising the conjugation of the compound of Formula III to a modified biomolecule wherein the modified biomolecule contains an alkynyl group comprising steps:
- (a) purifying the compound of Formula III; and
 - (b) reacting the purified compound of Formula III from step (a) with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the compound of Formula III to the modified biomolecule.
43. The process of claim 2, further comprising the conjugation of the compound of Formula V to a modified biomolecule wherein the modified biomolecule contains an alkynyl group comprising steps:
- (a) purifying the compound of Formula V; and
 - (b) reacting the purified compound of Formula V from step (a) with the alkynyl group of the modified biomolecule to form a 1,2,3-triazole group that covalently links the compound of Formula III to the modified biomolecule.
44. The process of claim 42 or 43, wherein the modified biomolecule is selected from a protein, a peptide, a nucleoside, a nucleotide, and a polynucleotide group that contains an olefin group.
45. A kit comprising:
- a. a first composition containing a silyl azide of Formula III:



b. a second composition comprising a benziodoxole of Formula IX



c. a third composition comprising water and optionally a second hydrogen bond donor wherein

R^4 is independently selected at each occurrence from alkyl and cycloalkyl;

R^5 is independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$;

R^6 and $R^{6'}$ are independently selected from $-O(C=O)R^7$, $-O(SO_2)(R^7)$, hydroxyl, and azido;

R^7 is independently selected at each occurrence from hydrogen, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, and trialkylsilyl, each of which R^7 other than hydrogen is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy; or

two R^7 groups may be brought together with the atoms to which they are attached to form a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, each of which ring is optionally substituted with one or more substituents selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, hydroxyl, halo, acylamino, aminoacyl, cyano, nitro, azido, acyl, acyloxy, carboxyl, carboxyl ester, alkanoyl, carboxamide, haloalkyl, and haloalkoxy;

R^8 and $R^{8'}$ are independently selected from hydrogen, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ may be brought together with the carbon to which they are attached to form a cycloalkyl or heterocycloalkyl ring, each of which ring is optionally substituted with one or more substituents selected from oxo, halo, cyano, azido, nitro, R^7 , $-OR^7$, $-N(R^7)(R^7)$, $-(C=O)R^7$, $-(C=O)OR^7$, $-(C=O)N(R^7)(R^7)$, $-O(C=O)R^7$, $-N(R^7)(C=O)R^7$, $-O(C=O)N(R^7)(R^7)$, and $-N(R^7)(C=O)OR^7$; or

R^8 and $R^{8'}$ are brought together to form an oxo or imino group;

Z is I; and

m is 1, 2, 3, or 4.

46. The kit of claim 45, wherein the second hydrogen bond donor selected from formic acid, an alkylcarboxylic acid, a (cycloalkyl)carboxylic acid, a (heteroalkyl)carboxylic acid, a (heterocycloalkyl)carboxylic acid, an arylcarboxylic acid, an (heteroaryl)carboxylic acid, sulfuric acid, an alkylsulfonic acid, a (cycloalkyl)sulfonic acid, a (heteroalkyl)sulfonic acid, a (heterocycloalkyl)sulfonic acid, an arylsulfonic acid, and a (heteroaryl)sulfonic acid.

47. The kit of claim 45, wherein the second hydrogen bond donor is trifluoroacetic acid.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/39925

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07D 307/77; C07F 7/10 (2019.01)

CPC - C07D 307/77; C07F 7/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	(YUAN, YA et al.) 'Iron-Catalyzed Direct Diazidation for a Broad Range of Olefins'; 11 January 2016, Angewandte Chemie; Volume 128, Issue 2, pages 544-548; page 545, first column, table 1; page 545, second column, table 2	1-4, 5/1, 5/3, 6/1, 6/3, 7/1, 7/3, 8/6/1, 8/6/3, 9/6/1, 9/6/3, 10/6/1, 10/6/3, 11/6/1, 11/6/3, 12/6/1, 12/6/3, 13/2, 13/4, 14/2, 14/4, 15/2, 15/4, 32-33, 34/32-33, 35/34/32-33, 42-43, 44/42-43, 45-47
A	CN 106008403 A (FUDAN UNIV) 12 October 2016; English translation; claim 1	1-4, 5/1, 5/3, 6/1, 6/3, 7/1, 7/3, 8/6/1, 8/6/3, 9/6/1, 9/6/3, 10/6/1, 10/6/3, 11/6/1, 11/6/3, 12/6/1, 12/6/3, 13/2, 13/4, 14/2, 14/4, 15/2, 15/4, 32-33, 34/32-33, 35/34/32-33, 42-43, 44/42-43, 45-47
A	US 6,232,451 B1 (CLAASSEN) 15 May 2001; claim 1	1-4, 5/1, 5/3, 6/1, 6/3, 7/1, 7/3, 8/6/1, 8/6/3, 9/6/1, 9/6/3, 10/6/1, 10/6/3, 11/6/1, 11/6/3, 12/6/1, 12/6/3, 13/2, 13/4, 14/2, 14/4, 15/2, 15/4, 42-43, 44/42-43

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 August 2019 (13.08.2019)

Date of mailing of the international search report

04 SEP 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/39925

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/0077990 A1 (ZHANG, XP) 29 March 2012; abstract; paragraphs [0030]-[0033], [0044]-[0045]	1-4, 5/1, 5/3, 6/1, 6/3, 7/1, 7/3, 8/6/1, 8/6/3, 9/6/1, 9/6/3, 10/6/1, 10/6/3, 11/6/1, 11/6/3, 12/6/1, 12/6/3, 13/2, 13/4, 14/2, 14/4, 15/2, 15/4, 42-43, 44/42-43
A	US 2015/0057419 A1 (UNIVERSITY OF CONNECTICUT) 26 February 2015; abstract; figure 1	1-4, 5/1, 5/3, 6/1, 6/3, 7/1, 7/3, 8/6/1, 8/6/3, 9/6/1, 9/6/3, 10/6/1, 10/6/3, 11/6/1, 11/6/3, 12/6/1, 12/6/3, 13/2, 13/4, 14/2, 14/4, 15/2, 15/4, 32-33, 34/32-33, 35/34/32-33, 42-43, 44/42-43, 45-47
A	PUBCHEM. CID 74955. 27 March 2005, pp. 1-12. Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/compound/74955 >; page 2, formula	32-33, 34/32-33, 35/34/32-33, 45-47

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/39925

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 16-31, 36-41
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.